BEFORE THE SCIENCE SUBCOMMITTEE OF THE INDEPENDENT CITIZENS' OVERSIGHT COMMITTEE TO THE CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE ORGANIZED PURSUANT TO THE

REGULAR MEETING

CALIFORNIA STEM CELL RESEARCH AND CURES ACT

LOCATION: AS INDICATED ON THE AGENDA

TUESDAY, JULY 20, 2010 10: 30 A. M. DATE:

BETH C. DRAIN, CSR REPORTER:

CSR. NO. 7152

BRS FILE NO.: 87839

INDEX

I TEM DESCRIPTION	PAGE	NO
CALL TO ORDER		3
ROLL CALL		3
UPDATE ON PROPOSAL REGARDING POLICY FOR US OF UNUSED DISEASE TEAM AWARD FUNDS FOR CLINICAL TRIALS	SE	7
UPDATE ON PROPOSAL COMMISSIONING IOM REPORT ON CIRM	3	80
DISCUSSION AND CONSIDERATION OF CHANGES TO EXTRAORDINARY PETITION AND GRANT ADMINISTRATION APPEALS PROCESSES) 4	łO
PUBLIC COMMENT	6	8

_	DARRISTERS REPORTING SERVICE
1	TUESDAY, JULY 20, 2010
2	10: 30 A. M.
3	
4	MS. KING: THANK YOU FOR ALL JOINING. WE
5	KNOW SEVERAL OF YOU ARE ALREADY ON THE CALL. I'M
6	GOING TO TURN IT OVER TO OUR CHAIR FOR THE
7	SUBCOMMITTEE, JEFF SHEEHY, AND WE'LL GET STARTED.
8	CHAIRMAN SHEEHY: THANK YOU ALL FOR BEING
9	HERE TODAY. I THINK I'LL CALL THE MEETING TO ORDER.
10	MELISSA, DO YOU WANT TO START THE ROLL CALL.
11	MS. KING: YES. SO SUSAN BRYANT, I KNOW
12	YOU'RE JOINING US AS A MEMBER OF THE PUBLIC. THANK
13	YOU.
14	MARCY FEIT. MICHAEL FRIEDMAN.
15	DR. FRIEDMAN: HERE.
16	MS. KING: ROBERT KLEIN.
17	CHAIRMAN KLEIN: HERE.
18	MS. KING: FRANCISCO PRIETO. ED PENHOET.
19	PHIL PIZZO.
20	DR. PI ZZO: HERE.
21	MS. KING: JOHN REED. DUANE ROTH.
22	MR. ROTH: HERE.
23	MS. KING: JOAN SAMUELSON.
24	MS. SAMUELSON: HERE.
25	MS. KING: JEFF SHEEHY.
	3
	J

1072 BRISTOL STREET, COSTA MESA, CALIFORNIA 92626 1-800-622-6092 1-714-444-4100 EMAIL: DEPO@DEPO1.COM

1	CHAIRMAN SHEEHY: HERE.
2	MS. KING: OSWALD STEWARD.
3	DR. STEWARD: HERE.
4	MS. KING: AND ART TORRES.
5	CHAIRMAN SHEEHY: I THINK ART IS ON HIS
6	WAY. WILL WE HAVE A QUORUM?
7	MS. KING: ACTUALLY WE NEED MARCY AS WELL,
8	AND I KNOW SHE'S JOINING. I JUST TALKED TO HER
9	OFFICE THIS MORNING.
10	CHAIRMAN SHEEHY: IS JEANNIE ON THE LINE?
11	MS. KING: NO, SHE'S NOT, BUT WE NEED NINE
12	FOR A QUORUM. WE ONLY NEED EIGHT.
13	MS. SAMUELSON: HAS JOHN SLADEK BEEN
14	INCLUDED AS A MEMBER OF THE SUBCOMMITTEE?
15	MS. KING: HE'S NOT A MEMBER OF THE
16	SUBCOMMITTEE SINCE HE'S NOT ON THE BOARD, BUT HE IS
17	ABSOLUTELY MORE THAN WELCOME TO JOIN. I ACTUALLY
18	SENT HIM THE DIAL-IN AND CALLED HIM THIS MORNING AND
19	LEFT HIM A VOICE MAIL, UNDERSTANDING THAT HE MAY BE
20	INTERESTED IN JOINING. I'M NOT SURE WHETHER OR NOT
21	HE'S JOINING.
22	MS. SAMUELSON: THAT MAY HAVE BEEN TOO
23	LATE FOR HIM TO CHANGE SOME OTHER PLANS THAT HE HAD.
24	I'M GLAD YOU DID. I WOULD HOPE WE'D GET WORD TO HIM
25	SOONER IN THE FUTURE IF POSSIBLE.

4

1	MS. KING: I CAN DEFINITELY DO THAT. I
2	APOLOGIZE THAT WAS DELAYED. AND I'M HAPPY TO DO
3	THAT. I THINK IT MAKES A LOT OF SENSE.
4	DR. FONTANA: JEANNIE HERE.
5	MS. KING: AND ACTUALLY WE HAVE DR.
6	FONTANA AS WELL. MR. SHEEHY, WE DO HAVE A QUORUM.
7	ART TORRES IS PRESENT AND JEANNIE FONTANA.
8	CHAIRMAN SHEEHY: GREAT. OKAY. THEN I
9	GUESS WE'LL START INTO THE AGENDA, AND I'LL NOTE
10	THAT THE FIRST TWO ITEMS ARE ITEMS THAT ARE SLATED
11	FOR THE AUGUST ICOC MEETING THAT WERE FROM THE
12	PREVIOUS MEETING OF THE SCIENCE SUBCOMMITTEE.
13	THERE WERE OTHER ITEMS THAT WILL BE COMING
14	TO THE BOARD FROM THAT MEETING. ONE IS A
15	PRESENTATION TO GRANTS WORKING GROUP MEMBERS OF
16	INFORMATION ABOUT PROGRAMMATIC REVIEW AMONGST OTHER
17	THINGS. WE HAD A LENGTHY DISCUSSION LAST TIME, SO I
18	DON'T NEED TO REVIEW THAT.
19	HOPEFULLY THE IP TASK FORCE WILL MEET
20	BEFORE AS WAS DETERMINED AT THE LAST SCIENCE
21	SUBCOMMITTEE MEETING, THAT THE IP TASK FORCE WILL
22	MEET TO CONSIDER SUPPLEMENTS TO GRANTS TO ASSIST
23	OFFICES OF TECHNOLOGY AND LICENSING AT UNIVERSITIES
24	SO THAT WE'RE NOT LOSING ANY VALUABLE INTELLECTUAL
25	PROPERTY DUE TO THE SEVERE FUNDING RESTRAINTS THAT
	_

1	MANY OF THE UNIVERSITIES ARE UNDER AND THE CUTBACKS
2	THAT THEY'RE EXPERIENCING IN THESE OFFICES.
3	I THINK LAST TIME WE DOCUMENTED THAT THIS
4	WAS A PROBLEM THAT OTHER FOUNDATIONS WERE DEALING
5	AND GRAPPLING WITH TO MAKE SURE THAT THERE WAS AN
6	ADEQUATE AMOUNT OF CAPACITY WITHIN THE UNIVERSITIES
7	TO PATENT AND CAPTURE FOR THE PEOPLE OF CALIFORNIA
8	ALL THE POTENTIAL INTELLECTUAL WEALTH THAT MIGHT BE
9	THERE TO PAY BACK THESE BONDS.
10	SO HOPEFULLY STAFF HAS BEEN WORKING ON
11	THIS, PREPARING PROPOSALS. AND, DUANE, THERE IS A
12	PLAN TO HAVE THE IP TASK FORCE MEET BECAUSE I SURE
13	WOULD HATE TO LOSE, YOU KNOW, JUST BECAUSE WE'RE IN
14	THIS TERRIBLE RECESSION, TO HAVE NO PATENT TO
15	HAVE LIMITED PATENTING AND LICENSING OF CIRM-FUNDED
16	I NVENTI ONS.
17	MR. ROTH: RIGHT. SO THAT'S ED PENHOET,
18	RI GHT?
19	MS. KING: YES. HE IS THE CHAIR OF THAT
20	SUBCOMMITTEE, AND I AM HAPPY TO CONTACT HIM ABOUT
21	THAT BASED ON THE INPUT OF THIS SUBCOMMITTEE AT THE
22	LAST MEETING, WHICH HE ATTENDED. I DON'T THINK IT
23	WILL BE A SURPRISE. HE'LL BE ON THIS CALL LATER
24	TODAY. HE JUST COULDN'T JOIN UNTIL ELEVEN.
25	CHAIRMAN SHEEHY: WE'LL JUST REMIND ED.
	6

1	THAT WAS SOMETHING THAT WAS SUPPOSED TO COME ON AS A
2	REPORT FROM THIS COMMITTEE OR FROM THE IP TASK FORCE
3	FOR THE AUGUST MEETING.
4	AND THEN IS STAFF PREPARED TO GIVE US AN
5	UPDATE ON THE USE OF UNUSED DISEASE TEAM RESEARCH
6	AWARDS FOR CLINICAL TRIALS?
7	MS. FEIT: THIS IS MARCY FEIT. I'VE
8	JOINED THE CONFERENCE.
9	CHAIRMAN SHEEHY: THANK YOU, MARCY.
10	DR. OLSON: YES, MR. CHAIR. I WANTED TO
11	COMMENT ON AN ITEM THAT YOU BROUGHT UP AT A PREVIOUS
12	SCIENCE SUBCOMMITTEE MEETING. AT THAT TIME THE
13	SCIENCE SUBCOMMITTEE ASKED THAT WE LOOK INTO WHAT
14	COULD BE DONE IF THERE WERE EXTRA FUNDS FROM DISEASE
15	TEAMS, FROM OUR CURRENT DISEASE TEAM I.
16	AS YOU ARE ALL AWARE, AWARDS UNDER THE
17	DISEASE TEAM RFA 09-01, THAT IS, DISEASE TEAMS I FOR
18	THE SAKE OF CLARIFICATION, ARE FOR WORK WITHIN THE
19	SCOPE DEFINED BY THAT RFA, WHICH DOES NOT EXTEND
20	BEYOND THE FILING OF AN IND. NOW, AS YOU ARE ALSO
21	AWARE, THAT WE CONTEMPLATE THAT THE UPCOMING DISEASE
22	TEAM II RFA, RFA 10-05, WILL ENCOMPASS MORE ADVANCED
23	WORK FOLLOWING THE FILING OF AN IND.
24	SO WE HAVE BEEN ASKED WHETHER DISEASE TEAM
25	I PROJECTS THAT CAN COMPLETE ITS OBJECTIVES MAY USE

1	ANY REMAINING FUNDS FOR MORE ADVANCED WORK ON THE
2	CANDIDATE THERAPEUTICS THAT WAS THE SUBJECT OF A
3	DISEASE TEAM I IND FILING. AND STAFF RESPONSE TO
4	THIS IS THAT WE WILL NOTIFY RECIPIENTS OF DISEASE
5	TEAM I AWARDS THAT WE CAN CONSIDER PROPOSALS FROM
6	AWARDEES FOR A CHANGE IN SCOPE.
7	SO IT WOULD FOLLOW UNDER OUR NORMAL
8	PROCEDURES FOR A CHANGE IN SCOPE TO INCLUDE
9	ADDITIONAL WORK THAT WOULD BE WITHIN THE SCOPE OF A
10	DISEASE TEAM II RFA.
11	WE WILL WORK WITH ANY INTERESTED DISEASE
12	TEAM I PI AND THEIR TEAM TO ENSURE THAT ANY MODIFIED
13	RESEARCH PLAN INCLUDES APPROPRIATE MILESTONES,
14	INCLUDING GO/NO-GO EVALUATION POINTS AND TIMELINES.
15	THE MODIFIED RESEARCH PLAN, INCLUDING ANY CLINICAL
16	COMPONENTS, MUST BE FEASIBLE WITHIN THE AMOUNT OF
17	THE AWARD THAT WAS PREVIOUSLY APPROVED BY THE BOARD
18	AND AS STATED IN THE NOTICE OF GRANT AWARD.
19	AND THEN THE OTHER POINT THAT WE WOULD
20	CONSIDER IMPORTANT IS, AS WITH OTHER MAJOR DECISIONS
21	INVOLVING DISEASE TEAM PROJECTS, THE PRESIDENT AND
22	THE VP OF R&D WILL SEEK ADVICE FROM AN EXPERT
23	ADVISORY COMMITTEE AS DESCRIBED IN THE RFA FOR
24	DISEASE TEAM I.
25	SO THOSE ARE MY COMMENTS ON THAT AND THAT
	8
	i U

1	IS OUR PROPOSAL.
2	CHAIRMAN SHEEHY: WELL, I HAD ONE
3	QUESTION, AND THEN I KNOW BOB HAS A QUESTION. IT'S
4	NOT CLEAR TO ME THAT THIS ISSUE ABOUT BEING
5	FEASIBILITY WITHIN THE FUNDING AVAILABLE WILL
6	ACTUALLY CAPTURE THE LEVERAGING OPPORTUNITIES THAT
7	MIGHT BE AVAILABLE. LET'S SAY THAT THERE IS MONEY
8	LEFT OVER. AND SINCE THERE ARE TWO HIV GRANTS, I
9	CAN EASILY IMAGINE EITHER NIH OR GATES OR AMFAR OR
10	ANY OF THE OTHER FUNDERS IN HIV RESEARCH, WE HAVE
11	SOMEBODY WITH AN IND HAS MONEY TO GET HALF OF A
12	CLINICAL TRIAL, AND ONE OF THESE OTHER FUNDERS MIGHT
13	HAVE A WILLINGNESS TO DO THAT. BUT I THINK IF WE
14	BURDEN THE DISEASE TEAMS WITH THE EXPECTATION, IF
15	WE LET ME BE MORE CLEAR. IF WE DON'T GIVE THEM
16	THE OPPORTUNITY TO LEVERAGE THESE FUNDS, THEN I
17	THINK WE'RE SETTING THEM UP FOR FAILURE. IT'S NOT
18	CLEAR THAT COMING OUT OF AFTER HAVING FINISHED A
19	PROJECT THAT THEY ACTUALLY WROTE A BUDGET FOR IN
20	ORDER TO COMPLETELY DO THE WORK THAT THEY SCHEDULED
21	TO GET THERE FASTER, THAT THEY NECESSARILY THEN HAVE
22	THE COMPLETE FUNDING LEFT OVER TO DO A CLINICAL
23	TRI AL.
24	SO I DON'T WANT US TO GET CAUGHT. THE
25	IDEA IS TO LEVERAGE IN MY MIND.

1	CHAIRMAN KLEIN: IF I COULD MAYBE FOLLOW
2	ON THIS POINT IS THAT, DR. OLSON, FIRST OF ALL, I
3	THINK EMBEDDED IN WHAT YOU ARE SAYING IS THE STAFF
4	WOULD NEED TO REVIEW THE BUDGET THAT THEY'RE
5	PROPOSING. AND THAT IF IN ADDITION TO THE RESIDUAL
6	FUNDS THEY HAVE FROM DISEASE TEAMS, THEY HAD PRIVATE
7	COMMITMENT OF FUNDS OR NIH COMMITMENT, YOU WILL LOOK
8	AT THE ENTIRE AVAILABLE FUNDS, INCLUDING THE
9	RESI DUAL FUNDS.
10	DR. OLSON: I DON'T THINK WE'RE PRECLUDING
11	LEVERAGI NG.
12	CHAIRMAN KLEIN: WHAT YOU'RE SAYING IS
13	THAT FEASIBLE GIVEN THE RESIDUAL FUNDS INCLUDING
14	OTHER FUNDS THEY HAVE AVAILABLE TO COMPLETE THAT
15	WORK THEY'RE PROPOSING.
16	DR. OLSON: RI GHT.
17	CHAIRMAN SHEEHY: WE'RE MAKING A CHICKEN
18	AND EGG ARGUMENT. I MEAN IT'S KIND OF LIKE THEY MAY
19	NOT BE ABLE TO GET THE ADDITIONAL FUNDS AND NOT
20	HAVING THE OKAY FROM US TO USE THE FUNDS THAT THEY
21	HAVE AVAILABLE.
22	CHAIRMAN KLEIN: WHAT I UNDERSTAND
23	CHAIRMAN SHEEHY: I MEAN WOULD WE BE
24	CONTINGENT ON THEM HAVING ATTAINED THE MATCHING
25	FUNDS OR LEVERAGING FUNDS? WOULD WE JUST SAY YOU
	10

1	DON'T HAVE THE MONEY; WE WANT OUR MONEY BACK?
2	CHAIRMAN KLEIN: SO WHY DON'T WE TAKE THAT
3	AS A SERIES OF QUESTIONS, JEFF, AND BREAKING THEM
4	DOWN. THE FIRST ISSUE IS IF THEY HAD \$3 MILLION OF
5	RESIDUAL FUNDS AND THEY SAID WE HAVE A LIMITED SCOPE
6	HERE, WE'RE GOING TO ASK THAT WE BE ALLOWED TO GO
7	THROUGH AND SPECIFICALLY MANUFACTURE THE CELLULAR
8	PRODUCT TO BE USED IN THE TRIAL AND STOP THERE. SO
9	THEY HAD A LIMITED SCOPE IN MOVING FORWARD ON THEIR
10	PHASE I. WOULD THAT OPTION BE SOMETHING THAT WOULD
11	BE REASONABLE TO PROPOSE?
12	DR. OLSON: FIRST, THAT WOULD BE PART OF
13	WHAT I WOULD EXPECT THEM TO HAVE COMPLETED BY THE
14	END OF THE DISEASE TEAM. BUT I DO THINK THAT, YES,
15	THEY COULD PROPOSE AN END POINT THAT WAS COMPATIBLE
16	WITH WHATEVER FUNDS THEY HAD LEFT. IF THEY WERE
17	ABLE TO STATE THAT THEY ANTICIPATED THE ADDITION OF
18	EXTRA FUNDS PENDING THIS, BUT THOSE ARE CONTINGENT
19	FUNDS, RIGHT. YOU DON'T KNOW THAT THEY'RE THERE,
20	BUT THERE WOULD BE SOME ACTIVITIES I'M SURE THAT
21	THEY COULD PROPOSE; I.E., SITE INITIATION. IT DOES
22	COST MONEY TO SET UP SITES. IT TAKES TIME. AND TO
23	ACTUALLY, ASSUMING THEY'D RECEIVED IND APPROVAL,
24	THEN THEY WOULD PROBABLY GO INTO SITE INITIATION.
25	THEY PROBABLY IDENTIFIED SITES, BUT THEY PROBABLY

1	HAVE NOT INITIATED SITES.
2	SO I THINK THEY WOULD BE ABLE TO CHOOSE
3	ACTIVITIES THAT MOVED THE PROGRAM FORWARD AND WERE
4	WITHIN THE SCOPE OF WHATEVER REMAINING FUNDS THEY
5	HAD. AND IF THEY HAD ALREADY FUNDS COMMITTED, THEN
6	CERTAINLY THAT COULD PLAY IN. IF THEY HAD THE
7	POTENTIAL FOR COMMITMENT, THAT WE'D HAVE TO THINK
8	ABOUT.
9	DR. TROUNSON: I'M NOT SURE HOW THIS
10	REALLY NEGATIVELY AFFECTS IT BECAUSE THAT'S
11	HAPPENING ALL THE TIME. THERE'S MORE MONEY COMING
12	INTO THESE PROJECTS AS THEY MOVE ALONG. SO IT'S
13	PROBABLY LIKELY THAT THEY'LL GET THERE FASTER
14	BECAUSE THERE'S ADDITIONAL FUNDS COMING INTO THE
15	PROJECT SO THAT THEY'LL MEET THEIR PRESUMABLY
16	MEET THEIR MILESTONES MORE QUICKLY OR MORE
17	EFFECTIVELY. AND THE ONLY THING THAT WE NEED TO DO
18	IS ENSURE IF THERE'S MONEY LEFT OVER, THAT IT'S
19	BEING USED APPROPRIATELY.
20	SO I WOULD THINK IT COULD BE USED FOR
21	ESTABLISHMENT OF THEIR CLINICAL PROGRAM, AND THAT
22	SHOULD BE THAT THE FUNDS ARE BEING USED
23	APPROPRIATELY, NOT INAPPROPRIATELY, FOR THAT WORK.
24	AND IF THEY IT WILL BE REQUIRED, I'M
25	SURE, TO DO A WHOLE CLINICAL TRIAL, THAT THEY'LL

1	HAVE TO GET MORE MONEY FROM US IN AN ADDITIONAL
2	PROJECT OR GET MONEY FROM SOME OTHER PLACE. I THINK
3	THAT'S WHAT WOULD BE NORMALLY HAPPENING BECAUSE THE
4	COST OF THOSE CLINICAL PROJECTS ARE GOING TO BE MUCH
5	LARGER THAN THE AMOUNT OF MONEY THAT'S LEFT OVER
6	FROM THE PROJECT, I EXPECT.
7	SO I'M NOT SURE THAT IT REALLY HAS SUCH A
8	NEGATIVE EFFECT ON IT. I THINK WHAT WE'RE SAYING IS
9	THAT THE MONEY THAT'S LEFT OVER NEEDS TO BE
10	APPROPRIATELY UTILIZED FOR THE CLINICAL PROJECT.
11	CHAIRMAN KLEIN: JEFF, COULD WE ASK DUANE
12	OR DR. PIZZO OR ANYONE ELSE ON THE CALL. IT WOULD
13	SEEM IF OUR POSITION IS THAT IF THERE'S LEFT-OVER
14	MONEY AND THAT MONEY IS SUFFICIENT FOR SITE
15	INITIATION, AND IF THEY DEFINE THE TASK AS SITE
16	INITIATION, WOULDN'T THAT, IN FACT, PUT THEM IN A
17	POSITION TO MOVE FORWARD AND ATTRACT MORE FUNDS TO
18	GO FURTHER DOWNSTREAM?
19	MR. ROTH: I'LL COMMENT QUICK BECAUSE I'M
20	IN AN AIRPORT. SO I THINK, JEFF, IT'S INHERENT THAT
21	THEY WOULD LEVERAGE THE MONEY. THEY'RE NOT GOING TO
22	START A TRIAL IF THEY DON'T HAVE MONEY. THAT'S
23	REALLY UNETHICAL. I WORRY MORE ABOUT WHAT HAPPENS
24	TO THE MONEY THAT'S LEFT OVER IF THERE IS NO PATH
25	FORWARD. AND I WOULD THINK THAT THAT WOULD BE

1	SOMETHING WE NEED TO CONSIDER AS WELL.
2	DR. PIZZO: I AGREE WITH WHAT DUANE SAID
3	AND ACTUALLY WOULD JUST UNDERLINE HIS CAVEAT, WHICH
4	WOULD MEAN THE UNETHICAL PART. WE NEED TO MAKE SURE
5	THAT A TRIAL DOESN'T START IF THERE'S NOT FUNDING TO
6	COMPLETE IT BECAUSE THAT WOULD REALLY BE AN
7	EMBARRASSMENT FOR EVERYONE.
8	CHAIRMAN SHEEHY: DO WE HAVE OTHER BOARD
9	COMMENT?
10	MS. SAMUELSON: THIS IS JOAN WITH A
11	QUESTION. I'M WONDERING HOW THE FOLLOWING FACT
12	SITUATION WOULD FIT IN, WHICH I'VE SEEN IN THE
13	PARKINSON'S COMMUNITY. THAT IS, OBJECTIVES AREN'T
14	ACHIEVED, AND IT'S NOT CLEAR WHY, AND IT IS CLEAR
15	THAT THERE NEEDS TO BE MORE EFFORT APPLIED TO TRYING
16	TO FIGURE THAT OUT, TRYING TO FIGURE OUT WHETHER THE
17	TRANSLATIONAL OBJECTIVE IS APPROPRIATE, WHETHER
18	THERE'S SOMETHING ELSE THAT'S NEEDED, IS THERE NEWER
19	GROWTH FACTOR NEEDED, OR IS THERE SOMETHING ABOUT
20	THE CELLS THEMSELVES, IF YOU'RE IN A CELL
21	REGENERATION, THEIR RESTORATION OBJECTIVE. AND
22	THERE NEEDS TO BE MORE WORK OF A TRANSLATIONAL SORT,
23	BUT IT'S CLEARLY NOT READY FOR CLINICAL TRIAL, BUT
24	THAT THAT DOESN'T MEAN THAT THE PROJECT IS
25	I NAPPROPRI ATE.

1	WHERE DO FUNDS COME FROM TO FUND THAT
2	WORK, AND HOW DOES THAT PROCESS FIT INTO THIS?
3	DR. OLSON: SO THIS IS PAT OLSON. IF I
4	UNDERSTAND THE POINT CORRECTLY, THE IDEA IS THAT
5	MILESTONES PERHAPS ARE NOT ACHIEVED BECAUSE IT TURNS
6	OUT THAT MORE RESEARCH WORK NEEDS TO BE DONE. AND I
7	THINK THAT THAT REALLY IS A DISCUSSION WITH THE
8	OVERSIGHT ADVISORY COMMITTEE AS TO WHETHER THE PLAN,
9	THE RESEARCH PLAN, PROPOSED WILL, IN FACT,
10	CONTRIBUTE TO ADVANCING THE FIELD EVEN THOUGH THAT
11	THE OBJECTIVE OF THE RFA WILL NOT BE ACHIEVED. SO I
12	THINK THAT IS ONE OF THE KEY PURPOSES OF HAVING THAT
13	COMMITTEE IS TO UNDERSTAND THAT IF THE TEAM RUNS
14	INTO SOMETHING THAT SUGGESTS THAT THEIR PROPOSAL AS
15	ORIGINALLY CONFIGURED AND THE MILESTONES AS
16	ORIGINALLY LAID OUT IS JUST NO LONGER FEASIBLE OR
17	PRACTICAL, WHAT IS THEIR PLAN FOR MOVING FORWARD AND
18	FOR LEARNING SOMETHING.
19	MS. SAMUELSON: RIGHT. IT'S MORE
20	COMPLICATED THAN WAS INITIALLY UNDERSTOOD. AND THIS
21	HAS FREQUENTLY BEEN THE CASE IN THE CASE OF CELL
22	RESTORATION, CELL REGENERATION EFFORTS IN
23	PARKINSON'S BACK TO THE FIRST FETAL TISSUE DAYS.
24	DR. OLSON: DRUG DEVELOPMENT IS SELDOM
25	LI NEAR.

1	MS. SAMUELSON: EXACTLY. EXACTLY. SO
2	THAT MAY WELL BE AN AREA THAT, ASSUMING THAT THE
3	PROJECTS AREN'T JUST AUTOMATICALLY DEFUNCT AS A
4	RESULT, AND MY HUNCH IS THEY WON'T BE, THAT IT WOULD
5	BE WORTH A FURTHER INVESTMENT. THERE WILL BE FUNDS
6	AVAILABLE FOR THAT.
7	DR. FRIEDMAN: ARE WE LOOKING TO CRAFT
8	ARE WE JUST GETTING A SENSE OF THE FEELING OF THE
9	COMMITTEE? ARE WE ACTUALLY TRYING TO DRAFT A POLICY
10	AT THIS POINT? HELP ME UNDERSTAND WHAT IT IS YOU'D
11	LIKE TO ACCOMPLISH IN THE DISCUSSION.
12	CHAIRMAN SHEEHY: WELL, STAFF HAS BEEN
13	TASKED TO BRING A POLICY TO BE ADOPTED BY THE BOARD
14	AT THE AUGUST MEETING. SO I WAS JUST GETTING AN
15	UPDATE ON THAT.
16	DR. FRIEDMAN: GOT IT.
17	CHAIRMAN SHEEHY: IF THERE'S ANY FEEDBACK,
18	I THINK IT'S HELPFUL. THIS IS NOT DEFINITIVE.
19	WE'RE NOT GOING TO BE VOTING ON ANYTHING, BUT
20	OBVIOUSLY WE WANT TO IF THERE'S INPUT FROM
21	MEMBERS OF THE BOARD ON THIS, IT'S HELPFUL.
22	DR. FRIEDMAN: I THINK THAT'S AN EXCELLENT
23	SUGGESTION, JEFF. AND I'M REALLY GLAD YOU BROUGHT
24	IT BACK FOR THAT REASON. MY OWN RECOMMENDATION TO
25	STAFF IS DON'T TRY AND MAKE A VERY SPECIFIC POLICY

1	BECAUSE TRYING TO GUESS WHAT THE SPECIFIC
2	CIRCUMSTANCES WOULD BE, I THINK, IS DIFFICULT. EVEN
3	THOUGH IT WILL MAKE MORE WORK FOR US AS A BOARD, I
4	MIGHT RECOMMEND THAT WE LOOK AT THESE ON A
5	CASE-BY-CASE BASIS ABOVE A CERTAIN DOLLAR THRESHOLD
6	OR SOMETHING WITH, OF COURSE, THE RECOMMENDATION OF
7	THE SCIENTIFIC STAFF BECAUSE THAT'S CRITICAL. BUT I
8	CAN IMAGINE SO MANY DIFFERENT SCENARIOS, THAT IT'S
9	HARD TO CRAFT AN OVERALL POLICY RIGHT NOW THAT WON'T
10	TAKE JUST A HELL OF A LOT OF TIME AND ULTIMATELY
11	WON'T BE THAT USEFUL BECAUSE THE CIRCUMSTANCES WILL
12	BE SLIGHTLY DIFFERENT WHEN WE ACTUALLY GET TO IT.
13	CHAIRMAN SHEEHY: AND SO, DR. FRIEDMAN,
14	YOU WOULD ACTUALLY ADVISE BRINGING THESE BACK TO THE
15	BOARD ON A CASE-BY-CASE BASIS, AND REALLY THE
16	INSTRUCTION FROM STAFF BEING TO LET THEM KNOW THAT
17	THE OPTION IS OUT THERE?
18	DR. FRIEDMAN: YES. I KNOW THAT'S SORT OF
19	INEFFICIENT BECAUSE IT MEANS MORE STUFF FOR US TO
20	DO. AND I MAY RUE THIS RECOMMENDATION, BUT MAYBE I
21	WON'T BE ON THE BOARD AT THAT TIME, IN WHICH CASE I
22	WON'T REGRET IT QUITE SO MUCH. BUT I ACTUALLY WOULD
23	SIMPLY STATE WHAT YOU ALL JUST SAID, WHICH THERE IS
24	A FLEXIBILITY AND A RECOGNITION OF THE COMPLEXITY OF
25	WHOLE PROCESS, AND THAT WE AS A FUNDING ORGANIZATION

1	WOULD BE WILLING TO CONSIDER CIRCUMSTANCES. BUT I'M
2	JUST HAVING A LITTLE TROUBLE GUESSING HOW WELL WE'LL
3	BE ABLE TO WRITE THAT RIGHT NOW.
4	DR. PIZZO: I THINK MIKE MAKES A REALLY
5	IMPORTANT POINT. I AGREE WITH THAT ASSESSMENT THAT
6	YOU JUST PUT FORTH, MIKE. IN REALITY IT'S NOT THAT
7	WE'RE DEALING WITH DOZENS OF THESE THINGS. SO WHILE
8	WE'LL GETTING SOME EXPERIENCE, I THINK YOUR
9	SUGGESTION AND THE CAVEATS THAT YOU POSED ARE REALLY
10	WORTH CAREFUL CONSIDERATION. I CONCUR WITH THAT.
11	MS. FEIT: I AGREE. I THINK WE SHOULD
12	LEAVE OURSELVES AVAILABLE TO CONSIDER EACH AND EVERY
13	OPPORTUNITY ON ITS OWN MERIT SINGULARLY AT THIS
14	TIME.
15	MS. SAMUELSON: SAME HERE. JOAN.
16	CHAIRMAN SHEEHY: ALAN HAD A COMMENT AND
17	THEN BOB, BUT I WOULD LIKE TO KIND OF AGREE WITH
18	THAT TOO BECAUSE I CAN IMAGINE A SITUATION WHERE WE
19	MIGHT DECIDE TO FULLY FUND ONE OF THESE PROJECTS AS
20	A CLINICAL TRIAL. AND TAKING WHAT THEY HAVE LEFT
21	OVER, IF IT LOOKS REALLY GOOD, WHY WOULDN'T WE WANT
22	GET IN THE BALLPARK AND SEE IF WE CAN HIT A HOME
23	RUN?
24	DR. TROUNSON: I THINK THE MOST I THINK
25	THE MOST COMMON REQUEST THAT'S GOING TO COME TO US

1	IS WHETHER THEY CAN USE LEFT-OVER FUNDS IN ADDING TO
2	OTHER FUNDS THAT THEY WOULD BE SEEKING TO DO A
3	CLINICAL TRIAL. WOULD THEY BE ALLOWED TO DO THAT?
4	I THINK THE ANSWER TO THAT QUESTION SHOULD BE YES,
5	AND IT SHOULD BE ALLOWED, ABLE TO FORMULATE A
6	CLINICAL TRIAL. WHAT WE CAN'T SAY, OF COURSE, IS
7	WHETHER EVERYTHING IS IN PERFECT SHAPE UNTIL THEY
8	FIND THAT ADDITIONAL MONEY BECAUSE THAT WILL BE THE
9	FIRST QUESTION THAT WE'RE ASKED. CAN WE USE THE
10	LEFT-OVER MONEY?
11	SO I THINK WE SHOULD BE IN A POSITION TO
12	SAY YES. IT SHOULD BE USED APPROPRIATELY. AND THEN
13	WE HAVE TO HAVE SOME KIND OF REVIEW ABOUT WHETHER
14	THAT CLINICAL TRIAL IS THEN AN APPROPRIATE
15	EXPENDITURE. IF IT'S VERY DIFFERENT, YOU'RE GOING
16	TO HAVE TO GO TO A KIND OF CLINICAL GRANTS WORKING
17	GROUP REVIEW. I THINK WE SHOULD BE ABLE TO SAY,
18	YES, THOSE MONIES CAN BE USED FOR THAT PURPOSE, AND
19	THEN WE SHOULD THEN TAKE IT FROM THERE BECAUSE I
20	THINK PROBABLY EACH AND EVERY ONE OF THEM WILL
21	PROBABLY BE QUITE DIFFERENT.
22	BUT THE FIRST ANSWER THAT WE SHOULD BE
23	ABLE TO GIVE THOSE TEAMS IS, YES, IT SHOULD BE ABLE
24	TO BE USED APPROPRIATELY FOR CLINICAL TRIALS WORK.
25	CHAIRMAN KLEIN: SO I'D LIKE TO TRY AND

1	MERGE THESE COMMENTS BECAUSE I DO THINK IT'S
2	IMPORTANT TO BE ABLE TO COMMUNICATE WITH OUR
3	GRANTEES AND CREATE REASONABLE FRAMEWORK FOR
4	EXPECTATIONS. SO I ACTUALLY THINK THAT THE BASIC
5	CRITERIA THAT DR. OLSON LAID OUT, CREATE A SKELETON
6	SO PEOPLE HAVE REASONABLE EXPECTATIONS. THERE'S
7	GOING TO BE ADVISORY BOARD REVIEW. THERE'S GOING TO
8	BE A BUDGET REVIEW. WE'RE GOING TO HAVE MILESTONES.
9	WE NEED TO LAY OUT THAT FRAMEWORK AND THEN EMPOWER
10	THE SCIENTIFIC STAFF AND THE BOARD TO SCIENTIFIC
11	STAFF TO MAKE RECOMMENDATIONS, THE BOARD TO HAVE THE
12	POWER TO MAKE MODIFICATIONS AS ADAPT TO THE
13	SI TUATI ON.
14	BUT IT'S HELPFUL TO HAVE THE KIND OF
15	NARRATIVE DISCUSSION WE JUST HAD TODAY INCORPORATED
16	IN HERE THAT GIVES THEM THE UNDERSTANDING THAT, YES,
17	THESE FUNDS CAN BE, SUBJECT TO ALL THESE GUIDELINES,
18	WHICH THE BOARD AND THE CTAFE HAVE THE ARLLITY TO
	WHICH THE BOARD AND THE STAFF HAVE THE ABILITY TO
19	OVERWRITE IN A SPECIFIC APPROVAL ON A CASE STUDY
20	OVERWRITE IN A SPECIFIC APPROVAL ON A CASE STUDY
20 21	OVERWRITE IN A SPECIFIC APPROVAL ON A CASE STUDY BASIS, THAT THEY CAN COMBINE THESE FUNDS WITH OTHER
20 21 22	OVERWRITE IN A SPECIFIC APPROVAL ON A CASE STUDY BASIS, THAT THEY CAN COMBINE THESE FUNDS WITH OTHER FUNDS. THAT INFORMATION, GETTING IT OUT THERE,
20 21 22 23	OVERWRITE IN A SPECIFIC APPROVAL ON A CASE STUDY BASIS, THAT THEY CAN COMBINE THESE FUNDS WITH OTHER FUNDS. THAT INFORMATION, GETTING IT OUT THERE, LETTING PEOPLE UNDERSTAND THE BASIC RULES IS
19 20 21 22 23 24 25	OVERWRITE IN A SPECIFIC APPROVAL ON A CASE STUDY BASIS, THAT THEY CAN COMBINE THESE FUNDS WITH OTHER FUNDS. THAT INFORMATION, GETTING IT OUT THERE, LETTING PEOPLE UNDERSTAND THE BASIC RULES IS IMPORTANT AND THEN EMPOWERING EXCEPTIONS.

1	IT'S IMPORTANT FOR WHOEVER IS LISTENING THAT WE
2	ARTICULATE OUR BASIC DISCUSSION HERE. AS BOB HAS
3	ARTICULATED, WE NEED TO HAVE WHAT THE BASIC RULES
4	ARE GOING TO BE. SO I WOULD LIKE TO HEAR FROM
5	STAFF. I'M A GRANTEE. I GIVE PAT A CALL, LET'S
6	SAY. CAN I USE THESE RESIDUAL FUNDS? WHAT ARE THE
7	STEPS THAT WILL TAKE PLACE AFTER THAT REQUEST IS
8	MADE TO CIRM UNDER ALL OF OUR DISCUSSIONS FROM YOUR
9	PERSPECTI VE?
10	DR. OLSON: IT IS A CHANGE IN SCOPE
11	REQUEST UNDER THE SCOPE THAT WOULD BE ALLOWABLE
12	UNDER DISEASE TEAM II. WE HAVE A FORM THAT, IN
13	FACT, IS USED FOR CHANGE OF SCOPE. THEY WOULD HAVE
14	TO PROVIDE INFORMATION INDICATING WHAT ACTIVITIES.
15	AND SO WE WOULD SAY, ONCE THEY PUT IN, WE WOULD SAY
16	WE WOULD REQUIRE FROM YOU AN UNDERSTANDING OF WHAT
17	MILESTONES YOU SEE IN THE TIME AND HOW YOU WOULD USE
18	THOSE FUNDS GOING FORWARD, WHAT IS THE TIMELINE FOR
19	USE OF THE FUNDS, HOW DOES THIS FIT IN THE OVERALL
20	DEVELOPMENT STRATEGY, WHICH, BY THE WAY, WE WILL
21	HAVE BEEN WORKING WITH WITH THE TEAMS AS PART OF
22	DISEASE TEAM I. WE'LL BE KNOWING THAT ANYHOW. SO
23	ONCE WE HAVE THAT INFORMATION TO UNDERSTAND HOW IT'S
24	A CHANGE OF SCOPE, WE GO AND, AGAIN, THESE PROJECTS
25	WILL HAVE BEEN THROUGH ADVISORY OVERSIGHT COMMITTEE

1	MEETINGS DURING THE COURSE OF THEIR TENURE. SO IN
2	POINT OF FACT, THE ADVISORY OVERSIGHT COMMITTEE WILL
3	HAVE SOME FAMILIARITY WITH THE PROGRAM, WITH THE
4	PROPOSED CLINICAL PROGRAM, AND IT SHOULD BE NO
5	SURPRISE TO THEM TO SAY THAT THE NEXT STEPS IN
6	DEVELOPMENT ARE STEP X, BRING ON FIVE SITES; STEP Y,
7	START ENROLLMENT AT THIS TARGET.
8	SO IT'S JUST A CONTINUATION OF ACTIVITIES.
9	MR. TORRES: RIGHT. I GET THAT. BUT ONCE
10	THEY GIVE YOU ALL THAT INFORMATION, DOES THAT
11	TRIGGER A SUBSEQUENT OVERSIGHT COMMITTEE REVIEW?
12	DR. OLSON: IT DEPENDS, I THINK, ON THE
13	SCOPE OF WHAT'S TALKED ABOUT. IF IT REALLY IS JUST
14	A FIRST, THEY HAVE TO PASS THE 30-DAY IND REVIEW
15	PERIOD. AND ASSUMING THAT IT PASSED AND THEY
16	RECEIVE NO NOTICE OF CLINICAL HOLD, THEN THEY COULD
17	GO AHEAD AND START SITE SELECTION.
18	MR. TORRES: SO THE ADVISORY COMMITTEE
19	THEN RESPONDS TO YOUR INITIATION BASED UPON THE
20	REQUEST FOR WHAT DO WE DO WITH THESE
21	DR. OLSON: THE CHANGE OF SCOPE, DEPENDING
22	ON WHAT THEY ASK FOR, MIGHT BE SOMETHING THAT MAY OR
23	MAY NOT REQUIRE ADVISORY OVERSIGHT.
24	MR. TORRES: SO YOU DECIDE MAYBE IT
25	DOESN'T REQUIRE IT. AT WHAT POINT DOES DR.

1	FRIEDMAN'S ANALYSIS COME INTO PLAY WHEN THE BOARD
2	ENTERS THE PICTURE?
3	DR. OLSON: THE BOARD DOES NOT NORMALLY
4	ENTER IN THE CHANGE OF SCOPE REQUESTS. AND SO
5	ACTUALLY THAT WAS A LITTLE BIT OF A NUANCE. I MEAN
6	THE BOARD CERTAINLY COULD BE INFORMED OF UPDATES TO
7	HOW DISEASE TEAMS ARE PROGRESSING OR SUCH, BUT
8	NORMALLY A BOARD DOES NOT PARTICIPATE IN REQUESTS
9	FOR CHANGE OF SCOPE ON PROGRAMS. SO THIS IS A NEW
10	FEATURE.
11	MS. BAUM: I JUST WANTED TO NOTE FOR THE
12	RECORD THAT IT'S NOT JUST A NORMAL PRACTICE. IT'S
13	WHAT'S REQUIRED UNDER THE REGULATIONS IS THE
14	PRESIDENT WOULD NORMALLY OR IS AUTHORIZED TO MAKE
15	THOSE DECISIONS ON CHANGE OF SCOPE. SO I WANTED TO
16	MAKE THAT NOTATION.
17	AND I ALSO WANTED TO NOTE THAT WHEN I WAS
18	LISTENING TO THE CONVERSATION, I THINK I NOTED DR.
19	FRIEDMAN AS SAYING THAT NOT EVERYTHING IN HIS MIND
20	NEEDED TO GO TO THE BOARD EITHER. THERE WAS GOING
21	TO BE SOME CRITERIA BECAUSE OTHERWISE YOU MIGHT BE
22	SLOWING THE PROCESS DOWN UNNECESSARILY.
23	MR. TORRES: I DON'T WANT TO PUT WORDS IN
24	YOUR MOUTH, MIKE. I DON'T THINK YOU WERE SAYING YOU
25	WEREN'T ADVERSE TO REVIEWING MORE WORK, BUT RATHER

1	WHAT WOULD TRIGGER THAT REVIEW.
2	DR. FRIEDMAN: EXACTLY. AND I HAVE NO
3	DESIRE FOR US TO BE INVOLVED IN THE LARGE NUMBER OF
4	RELATIVELY MINOR REQUESTS THAT YOU GET. I THOUGHT
5	WE WERE MAKING A POLICY FOR SUBSTANTIAL AMOUNTS OF
6	MONEY BEING LEFT OVER OR UNIQUE CONSIDERATIONS. IF
7	WE'RE TALKING ABOUT SOMEBODY OUT OF A \$10 MILLION
8	GRANT ENDS UP WITH \$50,000 AT THE END, THE BOARD
9	DOESN'T WANT TO BE INVOLVED IN THAT. SO I'M ONLY
10	TALKING ABOUT THE BIGGER THINGS OR MORE
11	CONTROVERSIAL THINGS OR MORE COMPLICATED THINGS. I
12	CERTAINLY DON'T WANT TO CREATE A LAYER OF
13	BUREAUCRACY THAT THE STAFF HAS TO DEAL WITH BECAUSE
14	THAT'S COUNTERPRODUCTIVE ALSO.
15	DR. PIZZO: I THINK WE I ASSUMED THAT
16	THAT'S WHAT MIKE WAS TALKING ABOUT AS WELL.
17	CHAIRMAN KLEIN: IF THERE'S A \$20 MILLION
18	GRANT, THERE'S 10 MILLION LEFT OVER, AND WE ARE
19	ABOUT TO USE THOSE FUNDS TO START A BREAKTHROUGH
20	HUMAN TRIAL, I THINK IT WOULD BE GOOD TO REVISIT
21	THAT AT THE BOARD LEVEL JUST TO HAVE AN
22	INFORMATIONAL BRIEFING AND MAKE SURE THAT WE CHECK
23	IN TO MAKE CERTAIN THAT WE'RE ALL ON BOARD WITH
24	EXACTLY
25	MR. TORRES: HOW DO WE CHECK IN? HOW ARE
	24

1	WE NOTICED THAT THAT'S OCCURRING?
2	CHAIRMAN KLEIN: WELL, LET'S WAIT FOR THE
3	COMMITTEE LET'S WAIT FOR THE STAFF TO BRING THIS
4	TO THE BOARD. AND THEY CAN SET SOME GUIDELINES, BUT
5	CERTAINLY I THINK WHAT WE'RE TALKING ABOUT IS A
6	MAJOR EVENT HERE AND MAJOR FUNDING.
7	MS. FEIT: I THINK IN FAIRNESS TO OUR
8	POLICIES AND OUR PROCEDURES, I THINK WE HAVE TO BE
9	CAREFUL THAT WE DON'T GET OURSELVES INTO A POSITION
10	WHERE WE'RE GOING FROM ONE GRANT TO ANOTHER GRANT TO
11	ANOTHER GRANT WITHOUT DUE PROCESS. I THINK WE HAVE
12	TO BE REAL CAREFUL ABOUT THAT GOING FORWARD. IF
13	THERE ARE LEFT-OVER FUNDS, THEN THERE ARE LEFT-OVER
14	FUNDS, BUT WE DON'T WANT TO GET INTO A POSITION
15	WHERE WE'RE GETTING TO A POINT WHERE WE'RE
16	COMFORTABLE WITH JUST GOING FROM ONE PROJECT TO
17	ANOTHER.
18	CHAIRMAN SHEEHY: ANY FURTHER BOARD
19	COMMENTS? SO PAT, DR. TROUNSON, DO YOU HAVE ENOUGH
20	TO KIND OF GET AN OUTLINE BECAUSE YOU'RE GOING TO BE
21	BRINGING A FORMAL POLICY TO THE BOARD IN AUGUST?
22	DR. TROUNSON: SURE. I DON'T THINK
23	THERE'S ANY DOUBT THAT WE HAVE WHAT WE NEED. WE'LL
24	COME BACK TO YOU WITH SOMETHING THAT HOPEFULLY WILL
25	SUIT EVERYBODY.
	25

1	CHAIRMAN SHEEHY: EVEN THOUGH THIS IS NOT
2	AN ITEM UNDER CONSIDERATION, WE DO HAVE A PUBLIC
3	COMMENT HERE IN SAN FRANCISCO. ALWAYS HAPPY TO TAKE
4	PUBLIC COMMENT. IF AT ANY OF THE OTHER SITES IF
5	THERE ARE PEOPLE FROM THE PUBLIC WHO WOULD LIKE TO
6	SPEAK TO THIS, HAPPY TO HEAR FROM THEM, BUT IT'S NOT
7	FORMALLY NEEDED.
8	MR. REED: THIS IS DON REED. THIS IS VERY
9	EXCITING TO ME. CIRM HAS ALWAYS FOUND WAYS TO GET
10	MORE BANG FOR THE BUCK. AND THIS SEEMS TO ME TO BE
11	ONE. I LIKE THE IDEA OF THE GENERAL FRAMEWORK OF
12	THE PEOPLE BEING TOLD THAT IF YOU CAN FULLY
13	ACCOMPLISH YOUR MISSION AND YOU CAN END UP WITH SOME
14	MONEY LEFT OVER, THAT IT WOULD BE A GENERAL POLICY
15	THAT THAT WOULD BE YOU WOULD BE REWARDED FOR YOUR
16	CAREFULNESS BY GIVING STRONG CONSIDERATION TO TAKING
17	THIS TO THE NEXT STEP.
18	ALSO, IF THEY COULD KNOW THAT THEY'RE
19	WORKING TOWARD THIS AND THEY CAN SAY TO OTHER
20	PEOPLE, LOOK, WE'RE BEGINNING WITH A CHUNK OF CHANGE
21	ALREADY, WOULDN'T THAT BE MORE LIKELY TO ATTRACT
22	OUTSIDERS? I THINK THIS COULD BE AN INCENTIVE TO BE
23	CAREFUL, CAUTIOUS RATHER THAN IF THEY KNOW THE MONEY
24	IS ALL GOING TO USED UP, THERE'S A STRONG TEMPTATION
25	TO THINK, WELL, WE CAN ALSO DO THIS, THIS,

1	THIS. BUT IF THEY SAY WALL A MINUTE, THIS COULD
2	ALSO BE PART OF OUR NEXT STEP, I THINK THAT WOULD BE
3	A STRONG INCENTIVE TO BE CAUTIOUS.
4	THIS SEEMED LIKE A VERY EXCITING
5	POSSIBILITY TO ME.
6	CHAIRMAN SHEEHY: I DO THINK WE NEED TO BE
7	CLEAR THAT PEOPLE WHO THE INVESTIGATORS WHO COME
8	TO US FOR MONEY FULLY ANTICIPATE USING EVERY DIME IN
9	ORDER TO GET TO THE IND. AND WHAT WE'RE TRYING TO
10	ACCOUNT FOR IS SERENDIPITY BECAUSE IT'S CLEAR THEY
11	SCOPED OUT THE WORK THAT NEEDS TO BE DONE TO GET TO
12	THE IND. IF THERE WAS FAT IN THE BUDGET, I CAN
13	ASSURE YOU STAFF HAS BEEN VERY DILIGENT STEWARDS OF
14	STATE MONEY, AND THEY HAVE GONE THROUGH THESE GRANTS
15	WITH A FINE-TOOTHED COMB, MAKING SURE THAT THE RIGHT
16	SCIENCE IS GETTING DONE TO GET TO THE IND. BUT WHAT
17	WE'RE REALLY TRYING TO ACCOUNT FOR IS THAT
18	EVERYTHING GOES EXACTLY RIGHT, MAYBE IN SOME
19	CIRCUMSTANCES THERE'S SOME OTHER DISCOVERIES THAT
20	ARE NOT RELATED TO THIS TEAM THAT HELPED US JUMP A
21	STEP OR TWO, BUT WE'RE REALLY TALKING ABOUT
22	SERENDIPITY AND EXTREME GOOD FORTUNE. IT'S NOT
23	SOMETHING THAT WE WOULD ANTICIPATE BEING THE NORM.
24	THE BUDGETS ARE WRITTEN, THEY HAVE BEEN
25	EXAMINED, AND THERE'S A CLEAR ANTICIPATION THAT IT

1	WILL TAKE EVERY DIME THAT THEY HAVE TO GET THROUGH
2	THE WORK THAT THEY HAVE SCHEDULED. I JUST WANTED TO
3	MAKE THAT CLEAR SO PEOPLE DON'T THINK THAT WE'VE SET
4	OUT THESE LAVISHLY PADDED BUDGETS AND WE HAVEN'T
5	GONE OVER THEM CAREFULLY.
6	I THINK WHAT ALL OF US I KNOW FROM THE
7	HIV FIELD, WE'VE SEEN SOME REALLY INTERESTING
8	PRELIMINARY PUBLICATIONS PUBLICATIONS OF
9	PRELIMINARY WORK THAT LOOKS VERY EXCITING. BUT I
10	FULLY ANTICIPATE THAT THEY LL NEED EVERY DIME THAT
11	THEY HAVE TO GET TO THE FINISH LINE. JUST IN CASE
12	IS WHAT WE'RE TRYING TO CAPTURE. WE DO WANT TO
13	ENCOURAGE THEM TO GO AS FAST AS THEY CAN OBVIOUSLY
14	BECAUSE THERE ARE PATIENTS THAT ARE WAITING FOR
15	THESE CURES.
16	DR. TROUNSON: JEFF, MAY HAPPEN MORE
17	FREQUENTLY THAN YOU THINK BECAUSE IF IT LOOKS LIKE
18	THERE'S GOING TO BE A SUCCESSFUL PROGRAM, THEN MAYBE
19	INVESTMENTS COME IN EARLIER. AND THEY MAY COME IN
20	THE PRECLINICAL AREA OF THE DISEASE TEAM, AND THAT
21	MIGHT ACCELERATE THE PROJECTS. I THINK THEIR VIEW
22	WOULD BE, THEN, THEY WOULD BE COMFORTABLE DOING THAT
23	IF THEY KNEW THAT THE FUNDS WE WERE ALLOCATING COULD
24	ALSO GO ACROSS TO THE NEXT STAGE.
25	SO I THINK IT'S A VERY IMPORTANT NOTION
	28

1	THAT WE SAY THAT IF THERE IS A SAVINGS ON THE
2	PROJECT FROM OUR MONEY, AS LONG AS IT'S BEING USED
3	APPROPRIATELY, YES, WE'RE STRONGLY IN FAVOR OF IT.
4	AND SO YOU START WITH THAT UNLESS IT'S
5	I NAPPROPRI ATE.
6	CHAIRMAN SHEEHY: THANK YOU, DR. TROUNSON.
7	SO UNLESS ANYONE HAS ANY OTHER COMMENTS, I THINK
8	WE'RE READY TO MOVE ON TO AGENDA ITEM NO. 4.
9	MS. SAMUELSON: I'VE GOT A QUICK
10	PROCEDURAL QUESTION, JEFF. DON'T WE NEED TO BE
11	AVAILABLE TO THE PUBLIC AND PROVIDING THEM
12	OPPORTUNITIES TO SEE EVERYTHING THAT WE DO? THAT
13	WAS MY IMPRESSION. AND IT SOUNDED LIKE YOU WERE
14	SAYING I'M JUST CURIOUS THAT IT WASN'T NECESSARY
15	IN THIS CONTEXT.
16	CHAIRMAN SHEEHY: FOR THIS PARTICULAR ITEM
17	IN TERMS OF PUBLIC COMMENT?
18	MS. SAMUELSON: I THOUGHT YOU WERE
19	REFERRING TO THE MEETING AS A WHOLE, THAT IT DIDN'T
20	NEED PUBLIC COMMENT.
21	CHAIRMAN SHEEHY: ONLY FOR THAT ITEM
22	BECAUSE IT'S NOT AN ITEM ON WHICH WE'RE TAKING
23	ACTION. IT'S JUST A DISCUSSION ITEM. PUBLIC
24	COMMENT ISN'T REQUIRED, BUT I WANTED TO MAKE CLEAR
25	THAT, NO. 1, WE ARE OPEN TO THE PUBLIC, SO WE'RE
	20

1	ALWAYS HAPPY TO TAKE PUBLIC COMMENT IF SOMEONE IS
2	INTERESTED IN OFFERING SOME INSIGHT, BUT THAT IT
3	WASN'T A REQUIREMENT THAT WE GO BY EACH SITE, CHECK
4	FOR PUBLIC COMMENT BEFORE WE TAKE A VOTE.
5	MS. SAMUELSON: GOT IT.
6	CHAIRMAN SHEEHY: THAT WAS THE
7	DISTINCTION.
8	SO FOR NO. 4, UPDATE ON CONSIDERATION OF
9	COMMISSIONING AN IOM REPORT ON PERFORMANCE OF CIRM.
10	DID YOU HAVE SOME COMMENTS YOU WANT, INSIGHTS? I
11	JUST WANT CAN I REPEAT OUR CONVERSATION FOR
12	BACKGROUND? ONE OF THE THINGS THAT WE HAD DISCUSSED
13	WAS THE POTENTIAL MAYBE OF THIS PARTICULAR REPORT
14	PERHAPS TAKING THE PLACE OF ONE OR TWO OF THE AUDITS
15	THAT HAVE BEEN REQUIRED IN SENATE BILL 1064. AND
16	THAT CLEARLY IS NOT PART OF THE SCOPE. IT WOULD NOT
17	BE PART OF THE SCOPE OF WHAT'S PROPOSED IN 1064.
18	SO THIS IS A SEPARATE REPORT THAT WILL BE
19	COMMISSIONED BY THE INSTITUTE IN ORDER TO GET A
20	COMPLETELY INDEPENDENT ANALYSIS OF OUR PERFORMANCE
21	TO DATE.
22	I THINK CHAIRMAN KLEIN HAS SOME COMMENTS.
23	THE MAIN THING IS JUST TO GET AN UPDATE THAT WE'RE
24	IN DISCUSSIONS WITH THE IOM, AND THIS IS SOMETHING
25	THAT WE CAN BRING UP FOR CONSIDERATION TO THE BOARD
	30

1	IN AUGUST.
2	CHAIRMAN KLEIN: SO WHAT'S IMPORTANT HERE
3	IS THAT IN REFINING THE VARIOUS STUDIES THAT ARE
4	ONGOING IN EVALUATING THE PERFORMANCE OF THE AGENCY,
5	THE IOM, WE EXPECT TO GET A PROPOSAL FROM THEM. AND
6	THAT PROPOSAL WOULD BE FUNDED, AT LEAST
7	THEORETICALLY, IF ACCEPTED BY THE BOARD, PARTIALLY
8	BY THIS AGENCY AND PARTIALLY BY OUTSIDE DONOR FUNDS
9	TO REDUCE THE COST TO THE STATE. BUT WHAT'S CLEAR
10	HERE IS THAT BECAUSE OF THE PRESTIGE OF THIS
11	ORGANIZATION, IF THEY SUBMIT A PROPOSAL WITH AN
12	EXPECTED TIMELINE OF ABOUT 15 MONTHS, IT WOULD BE
13	DONE ON A TIME FRAME WHERE THERE WAS AN ABILITY FOR
14	THE OUTSIDE PUBLIC TO REVIEW IT, FOR US TO REVIEW
15	ANY RECOMMENDATIONS, FOR THE AGENCY TO BE ABLE TO
16	ADAPT ANY RECOMMENDATIONS TO FURTHER IMPROVE OUR
17	PERFORMANCE. BUT FOR THE PUBLIC LOOKING AT WHETHER
18	DOWNSTREAM THEY WANT TO PROVIDE ADDITIONAL FUNDING
19	BECAUSE OF STRONG SCIENTIFIC PROGRESS, THIS WOULD BE
20	A SOLID MILESTONE, HOPEFULLY, OF INDICATING THE HIGH
21	PERFORMANCE OF THIS AGENCY.
22	SO CLEARLY THIS IS AN INDEPENDENT BODY.
23	CLEARLY IT'S PRESTIGIOUS ON ITS SCIENCE. I
24	SPECIFICALLY HAD A CONVERSATION WITH THEM ABOUT
25	WHETHER THEY WOULD HAVE WITHIN THEIR PROPOSED SCOPE

1	THE ECONOMIC ANALYSIS OF THE IMPACT OF THIS AGENCY
2	AND THE FUNDING STRUCTURE OF IT IN HELPING
3	CALIFORNIA AND SCIENCE MOVE FORWARD. SPECIFICALLY,
4	WHAT IS THE STRATEGIC VALUE OF HAVING STABLE FUNDING
5	AND ATTRACTING OUTSIDE FUNDS AND ATTRACTING PEOPLE
6	TO THE FIELD? THEY INDICATED THAT THEY HAVE
7	ECONOMISTS, A WHOLE SECTION OF ECONOMISTS, THAT ARE
8	MEMBERS OF THE IOM, AND THAT THEY WOULD HAVE THOSE
9	ECONOMISTS INVOLVED IN THAT PART OF IT SO THAT THEY
10	COULD CERTAINLY LOOK AT THE FUNDING SYSTEM AS BEING
11	IMPORTANT FOR CALIFORNIA AND THE COUNTRY. THEY
12	COULD LOOK AT, IN FACT, THE FUNDING SYSTEM FOR
13	PROVIDING THE STABILITY FOR INSTITUTIONS TO CREATE
14	ENTIRE DEPARTMENTS AND RECRUIT FACULTY AROUND THE
15	FIELD AS WELL AS OUTSTANDING STUDENTS FROM AROUND
16	THE COUNTRY AND AROUND THE WORLD.
17	SO THEY'RE PREPARED IN THIS PROPOSAL,
18	WHICH WE ARE LOOKING FORWARD TO RECEIVING, TO
19	LOOKING AT THE WHOLE SCOPE OF REVIEW AND IN A
20	TIMETABLE THAT I THINK WOULD PROVIDE, AS I SAID, A
21	VERY STRONG MILESTONE FOR THE PUBLIC'S REVIEW OF THE
22	AGENCY'S PERFORMANCE IN LOOKING AT WHETHER THIS
23	AGENCY SHOULD HAVE ADDITIONAL FUNDS IN THE FUTURE.
24	CHAIRMAN SHEEHY: SO ARE THERE ANY OTHER
25	COMMENTS FROM BOARD MEMBERS? I THINK THIS IS MOVING

1 FORWARD

DR. TROUNSON: THERE S A COUPLE OF POINTS,
ONE OF WHICH I THINK BOB TOUCHED ON, IS THAT THIS IS
A VERY COSTLY BUSINESS. SO IT'S GOING TO BE VERY
IMPORTANT TO GET SOME ADDITIONAL FUNDS BECAUSE WHEN
I SPOKE LAST TIME IT'S A POINT AND I THINK IT'S
AN IMPORTANT POINT, NO. 1, THAT WE PROBABLY NEED TO
GET SOME DONOR MONEY BECAUSE THIS IS GOING TO BE AN
EXPENSIVE ISSUE. WE HAVE HAD SOME CONVERSATIONS
WITH THE MEMBERS OF IOM, AND WE THINK THAT THAT'S
STILL GOING TO BE AROUND THAT KIND OF COST. SO WE
NEED TO REFLECT ON THAT. WE NEED TO MAKE SURE THAT
WE DO GET THOSE DONOR FUNDS. I THINK THAT'S VERY
IMPORTANT

THE OTHER THING IS THAT IT NEEDS TO BE

VERY MUCH LINKED TO WHEN WE WANT TO GO FORWARD TO

CALIFORNIA OR WHOMEVER FOR GETTING ADDITIONAL FUNDS.

AND I THINK WE NEED AS MUCH TIME AS POSSIBLE TO BE

ABLE TO DEMONSTRATE THE ECONOMIC BENEFITS OF WHAT

WE'RE DOING. ANY LONGER TIME WILL BE MORE AND MORE

HELPFUL FOR THAT. WE'VE GOT ONE REPORT, WHICH I

THINK JOHN ROBSON IS BRINGING TO THE BOARD SHORTLY

ON ONE CLINICAL TRIAL PROGRAM, BUT THAT'S A GOOD

START, BUT I THINK WE NEED SEVERAL OF THESE. AND

THEY'RE NOT GOING TO HAPPEN FOR A LITTLE WHILE. AND

1	SO I HOPE IT GIVES US A MAXIMUM OPPORTUNITY TO GET
2	THE MAXIMUM IMPACT FOR THE REPORT.
3	SO I THINK IT'S A VERY IMPORTANT JOB TO BE
4	DONE.
5	CHAIRMAN SHEEHY: JUST TO CLARIFY, SOME OF
6	US HAVE FIDUCIARY RESPONSIBILITIES TO OUR APPOINTING
7	OFFICERS AND OUR APPOINTING BODIES. AND IT WOULD
8	BE, NOTWITHSTANDING THE COST, WHICH \$1 MILLION OUT
9	OF THE BILLION WE'VE ALREADY SPENT, IF WE WANT TO GO
10	THROUGH THE BUDGET, AND REALLY I DON'T KNOW IF THIS
11	WOULD NOT BE ONE OF THE BETTER USES OF FUNDING, TO
12	BE ABLE TO CLEARLY SHOW THE PEOPLE OF CALIFORNIA
13	WHAT THE GOLD STANDARD, OBJECTIVE EVALUATION AGENCY
14	IN THIS COUNTRY, WHAT KIND OF WORK, WHAT KIND OF
15	PROGRESS WE'VE DONE.
16	I CERTAINLY DON'T WANT TO GO OFF THE BOARD
17	IN TWO YEARS WITHOUT THIS REPORT BEING FINISHED. I
18	FEEL VERY STRONGLY. THAT'S WHY I HAVE IT ON THE
19	AGENDA, TO MAKE SURE THAT THIS IS SOMETHING WE CAN
20	APPROVE IN AUGUST, THAT THIS IS SOMETHING THAT GOES
21	FORWARD. I DON'T THINK I COULD GO TO ANY MEMBER OF
22	THE PUBLIC, ANY EDITORIAL BOARD, ANY MEMBER OF THE
23	LEGISLATURE, THE GOVERNOR, ANY ELECTED OFFICIAL
24	WITHOUT SOME SORT OF EXTERNAL REVIEW OF WHAT'S GONE
25	ON WITH A BILLION DOLLARS OF THE TAXPAYERS MONEY,
	34
	34

1	ESPECIALLY IN THE MIDDLE OF THIS HORRIBLE RECESSION.
2	THERE'S SOME STATE WORKERS THAT ARE WORKING AT
3	MINIMUM WAGE, THANKS TO THE GOVERNOR. AND WE'RE
4	DOING AS HAS BEEN NOTED, WE'RE ABLE TO CONTINUE
5	TO DO OUR WORK.
6	I THINK THAT THERE'S A CERTAIN VALUE, AND
7	I THINK CHAIRMAN KLEIN HAS ALLUDED TO THIS, TO THE
8	CONSTANCY OF FUNDING, THE CERTAINTY OF FUNDING IN
9	ADVANCING MEDICAL SCIENCE, TO GETTING CURES FASTER.
10	I THINK WITH THIS REPORT, WE'LL BE ABLE TO SHOW THE
11	VOTERS THAT ACTUALLY THIS WAS A VERY GOOD INVESTMENT
12	AT A CRITICAL TIME FOR THE STATE OF CALIFORNIA, BOTH
13	IN TERMS OF THE FUTURE HEALTH OF CALIFORNIANS AND
14	OTHER PEOPLE IN THIS COUNTRY, BUT ALSO FOR OUR
15	ECONOMY AT A TIME WHEN FUNDS WERE REALLY RESTRICTED
16	FROM A LOT OF OTHER SOURCES.
17	SO I WOULD LIKE US TO BE ABLE TO MAKE THAT
18	ARGUMENT. I KNOW THIS WILL TAKE TIME, BUT I THINK
19	WE SHOULD GET ON WITH IT. AND IF IT COSTS US SOME
20	MONEY, I THINK THE CHAIR SEEMS CONFIDENT THAT WE CAN
21	FIND SOME OUTSIDE FUNDING, BUT WE SHOULD NOT SLOW
22	THIS DOWN. I THINK IT'S IMPORTANT FOR US, FOR OUR
23	CREDIBILITY BOTH AS INDIVIDUALS AND AS A BOARD.
24	DR. PIZZO, I KNOW THAT YOU WERE VERY
25	FAMILIAR WITH THIS.

1	DR. PIZZO: I AGREE WITH THE POINTS THAT
2	JEFF HAS PUT FORTH. I DO KNOW THE LOM PROCESS, AS
3	OTHERS DO, VERY WELL. I THINK IT'S PROBABLY THE
4	BEST PLACE FOR US TO GO, AND I TOTALLY CONCUR THAT
5	THIS IS A GOOD WAY OF HAVING A REALLY TRULY
6	INDEPENDENT CRITICAL ASSESSMENT. I SUPPORT IT, BUT
7	IT IS GOING TO BE EXPENSIVE AND IT WILL TAKE TIME.
8	CHAIRMAN KLEIN: I'D JUST LIKE TO
9	REEMPHASIZE. I THINK WE CAN FIND SUBSTANTIAL
10	PRIVATE DONATIONS, AS ALAN HAS REFERENCED, AS JEFF
11	HAS REFERENCED, AND THAT I WOULD REALLY SERIOUSLY
12	COMMIT SOME OF MY TIME TO MAKING SURE THAT WE HAVE
13	THAT HAPPEN. IN TIMES OF TIGHT CONSTRAINTS ON
14	BUDGETS EVERYWHERE, I WANT TO MAKE SURE WE HAVE
15	MAJOR PRIVATE CONTRIBUTIONS TO REDUCE THIS COST.
16	MS. BAUM: I JUST WANTED TO FOR THE RECORD
17	JUST ACKNOWLEDGE THE FACT THAT WE DO ALSO HAVE A
18	BLUE RIBBON PANEL OF TOP EXPERTS IN THE FIELD. I
19	DON'T THINK SUGGESTING THAT THE IOM IS ALSO NEEDED
20	SHOULD IN ANY WAY DIMINISH THE SUPPORT AND THE
21	CONTRIBUTIONS THAT THAT PANEL WILL BE MAKING IN
22	OCTOBER. THANK YOU.
23	MR. TORRES: THAT'S REQUIRED BY THE
24	STRATEGIC PLAN, REFERENCED BY THE INITIATIVE, BUT
25	THAT HAS NOTHING TO DO WITH WHAT THE OTHER ISSUES

1	ARE THAT WE'RE TALKING ABOUT.
2	DR. PIZZO: COULD SOMEONE
3	MR. TORRES: THERE ARE TWO SEPARATE TRACKS
4	HERE THAT WE WERE TALKING ABOUT, AND THAT'S WHY I
5	WANTED TO MAKE SURE THAT WE KNEW WHAT WE WERE
6	TALKING ABOUT.
7	DR. PIZZO: COULD SOMEONE PERHAPS SHARE,
8	SINCE I'M NOT SURE THAT I KNOW WHO'S ON THE BLUE
9	RIBBON PANEL, COULD WE TAKE A LOOK AT THAT LIST JUST
10	FOR OUR INFORMATION?
11	CHAIRMAN SHEEHY: SURE. PERHAPS STAFF
12	COULD SEND THAT AROUND TO THE MEMBERS.
13	DR. TROUNSON: SURE. IT'S BEEN OUT THERE
14	BEFORE, PHIL, BUT WE'LL SEND IT.
15	DR. PIZZO: I'M SORRY. I'M SURE IT'S JUST
16	ME.
17	DR. TROUNSON: WE'LL SEND IT TO YOU. I'LL
18	GET PAT TO DO THAT. ANYONE ELSE WHO NEEDS IT,
19	PLEASE LET US KNOW. WE'LL GET IT OUT TO YOU.
20	CHAIRMAN SHEEHY: HOW ABOUT WE JUST SEND
21	IT AROUND TO THE WHOLE COMMITTEE. PROVIDE IT TO
22	MELI SSA.
23	DR. OLSON: I JUST WANTED TO MAKE A POINT,
24	AND I THINK ALL THE COMMENTS ARE CERTAINLY TRUE.
25	THE IOM IS CLEARLY RECOGNIZED AS A BLUE RIBBON

1	INDEPENDENT GROUP. I'M SURE THAT THE COST CAN BE
2	DONE. I APPRECIATE THE VALUE, BUT I DO WANT PEOPLE
3	TO RECOGNIZE THAT THE COST IS NOT JUST IN MONEY.
4	THE COST IS IN STAFF TIME.
5	I HAD THE PLEASURE OF MEETING THE PROGRAM
6	OFFICER WITH, I BELIEVE, WHOM MEMBERS OF THE OFFICE
7	OF THE CHAIR STAFF HAS BEEN TALKING WITH THE IOM.
8	AND THEY DID CONFIRM WITH ME THAT IN POINT OF FACT
9	AN IOM REVIEW IS INCREDIBLY MANAGEMENT AND STAFF
10	TIME INTENSIVE. SO I DO NOT DISPUTE THE VALUE OF
11	THIS. I JUST WANT IT RECOGNIZED AND ACKNOWLEDGED
12	WHAT IT WILL TAKE TO UNDERTAKE SUCH A REPORT.
13	CHAIRMAN KLEIN: I THINK DR. OLSON'S POINT
14	IS CORRECT. AND ONE OF THE BENEFITS OF HAVING IT 15
15	MONTHS OUT IS TO MAKE SURE THAT THERE'S NO OVERLAP
16	WITH THE EXISTING PRESTIGIOUS PANEL THAT'S DOING
17	THEIR SCIENTIFIC REVIEW, WHICH THAT WORK WILL BE
18	DONE ESSENTIALLY IN THE NEXT 90 DAYS. BUT IT WAS
19	VERY IMPORTANT TO RECOGNIZE THAT IT IS A VERY
20	PRESTIGIOUS PANEL. I THINK, DR. PIZZO, YOU'LL SEE
21	WHO'S GOING TO REVIEW THE SCIENTIFIC STRATEGIC PLAN
22	PERFORMANCE. AND THAT WILL BE A GREAT INSTALLMENT
23	THAT WILL CONTRIBUTE TO THE ABILITY OF IOM TO HAVE
24	AN OVERVIEW ON WHAT WE HAVE DONE.
25	MS. SAMUELSON: BOB, THAT WILL ENCOMPASS A
	38

1	SCIENTIFIC REVIEW AS WELL, OF COURSE, RIGHT, IN
2	ADDITION TO AN ECONOMIC REVIEW AND SO ON. IT SEEMS
3	TO ME THAT THE MOST IMPORTANT THING IS THAT AT EVERY
4	POINT WE KNOW THAT WE'RE ON TRACK AS BEST WE CAN.
5	AND IF WE ARE NOT, HOW WE SHOULD BE TWEAKING WHAT
6	WE'RE DOING SO THAT WE GET THE BEST POSSIBLE
7	RESULTS, AND PRESUMABLY THIS IS A PIECE OF THAT.
8	MY HOPE IS THAT THE PROPOSAL WHEN IT COMES
9	TO THE BOARD WILL SPEAK TO THAT AS BEST IT CAN.
10	MR. TORRES: LET'S KEEP IN MIND AGAIN, NO.
11	1, THAT THE STRATEGIC PLAN REVIEW IS REQUIRED BY THE
12	INITIATIVE. SO WE UNDERSTAND THAT. WE'RE MANDATED
13	TO DO THAT. WE AREN'T MANDATED TO DO THE IOM, WHICH
14	IS WHY THE LEADERSHIP OF CIRM AND THE BOARD IN
15	CONJUNCTION AND WORKING TOGETHER ARE WANTING TO MAKE
16	SURE THAT WE HAVE ANOTHER REVIEW ON TOP OF THAT
17	REVIEW SO THAT WE HAVE A MACRO VIEW OF WHERE WE ARE
18	MOVING AND WHERE WE ARE HEADED.
19	CHAIRMAN SHEEHY: ANY OTHER BOARD
20	COMMENTS? WE HAVE A PUBLIC COMMENT HERE.
21	MR. REED: I THINK EVERYBODY IS THINKING
22	AT THE END OF THE 14 YEARS THAT THIS MUST GO ON,
23	THAT THE CALIFORNIA STEM CELL PROGRAM MUST BE
24	CONTINUED. I THINK THE IOM IS PART OF THAT.
25	NOW, OHIO IS DOING A LOT OF WORK ON
	20

1	STUDYING THE BENEFITS OF TARGETED FUNDING INTO
2	FORWARD LOOKING RESEARCH PROGRAMS SUCH AS
3	BIOMEDICINE. AND THEY'RE TRYING TO FIND EXACTLY
4	WHAT THE RESULTS WILL BE IN TERMS OF NEW JOBS, NEW
5	REVENUES. I WONDER IF IT WOULD BE POSSIBLE AS PART
6	OF THE IOM REVIEW TO HAVE SOMEBODY THAT'S PART OF
7	THAT PROCEDURE IN OHIO TO LEND US THAT KNOWLEDGE AS
8	PART OF THIS BECAUSE THAT'S WHAT'S GOING TO
9	DETERMINE LONG-TERM SUCCESS OF OUR PROGRAM IS HOW IT
10	AFFECTS PEOPLE. AND JOBS ARE A PART OF THAT
11	PICTURE. SO I THINK OHIO WILL BE GOOD TO CONSULT
12	WI TH.
13	CHAIRMAN SHEEHY: THANKS, DON. UNLESS
14	THERE'S ANY OTHER COMMENTS, I'M READY TO MOVE ON TO
15	AGENDA ITEM NO. 5, WHICH IS DISCUSSION OF AND
16	CONSIDERATION OF CHANGES TO THE EXTRAORDINARY
17	PETITION AND GRANT ADMINISTRATION APPEALS PROCESSES.
18	I THINK YOU GUYS, I HOPE EVERYONE HAS A COPY OF THE
19	DOCUMENTS. IT'S A PAGE AND A HALF.
20	I'LL JUST KIND OF GO OVER IT. AND HAPPY
21	FOR ALL COMMENTS AND CHANGES, ETC. I THINK ONE
22	THING THAT CONTINUES TO BEDEVIL US, BUT I THINK
23	WE'RE STUCK WITH, IS THE LINGUISTIC DIFFICULTIES IN
24	DISTINGUISHING BETWEEN THE APPEALS PROCESS AND THE
25	EXTRAORDINARY PETITION PROCESS. BUT THERE IS A

1	REASON FOR THAT.
2	THE ONLY REASON FOR AN APPEAL OF A
3	SCIENTIFIC SCORE OF A GRANT RECOMMENDATION FROM THE
4	GRANTS REVIEW GROUP IS CONFLICT OF INTEREST. AND SO
5	THE FORMAL APPEALS PROCESS CAPTURES THAT. HOWEVER,
6	AS THE PUBLIC BODY MEETING IN THE STATE OF
7	CALIFORNIA AND GOVERNED BY OPEN GOVERNMENT LAWS THAT
8	ARE ENSHRINED IN CALIFORNIA CONSTITUTION BY THE
9	WAY, I WANT STATE UP FRONT I DO NOT FIND THIS A
10	BURDEN. I FIND IT A POSITIVE FEATURE OF CALIFORNIA
11	PUBLIC POLICY PROCESS. BUT ANY MEMBER OF THE PUBLIC
12	CAN ADDRESS THE BOARD, CAN PROVIDE INFORMATION TO
13	THE BOARD REGARDING A MATTER UNDER CONSIDERATION BY
14	US.
15	AND GIVEN THAT, WE HAVE TRIED TO PROVIDE
16	SOME STRUCTURE FOR THAT, WHICH IS WHAT THE
17	EXTRAORDINARY PETITION PROCESS IS. NOW, A COUPLE
18	THINGS I WANT TO DO TODAY IS REINFORCE SOME OF THE
19	
	POLICIES THAT WE HAVE, SOME OF THE ASPECTS OF THAT
20	POLICIES THAT WE HAVE, SOME OF THE ASPECTS OF THAT POLICY THAT WE'VE KIND OF GOTTEN NEGLIGENT IN
20 21	
	POLICY THAT WE'VE KIND OF GOTTEN NEGLIGENT IN
21	POLICY THAT WE'VE KIND OF GOTTEN NEGLIGENT IN APPLYING. ONE IS THAT, AS ORIGINALLY CONCEIVED, THE
21 22	POLICY THAT WE'VE KIND OF GOTTEN NEGLIGENT IN APPLYING. ONE IS THAT, AS ORIGINALLY CONCEIVED, THE EXTRAORDINARY PETITION PROCESS DID NOT AUTOMATICALLY
21 22 23	POLICY THAT WE'VE KIND OF GOTTEN NEGLIGENT IN APPLYING. ONE IS THAT, AS ORIGINALLY CONCEIVED, THE EXTRAORDINARY PETITION PROCESS DID NOT AUTOMATICALLY GRANT AN APPLICANT REVIEW BY THE BOARD. IT IS

1	QUALIFY FOR DISCUSSION AND CONSIDERATION BY THE
2	BOARD.
3	WE OBVIOUSLY RECEIVE, AND I'M SURE, LIKE
4	MYSELF, ALL THE BOARD MEMBERS READ THE EXTRAORDINARY
5	PETITIONS AND CONSIDER THEM CAREFULLY. BUT UNLESS A
6	BOARD MEMBER SPECIFICALLY ASKS THAT AN EXTRAORDINARY
7	PETITION BE CONSIDERED OR PUBLIC COMMENT FROM A
8	MEMBER OF THE PUBLIC ABOUT INCLUDING AN APPLICANT
9	ABOUT THEIR APPLICATION, CONSIDERATION IS NOT
10	AUTOMATI C.
11	JUST TO REEMPHASIZE, AS A MATTER OF
12	PROCESS, THAT SIMPLY FILING AN EXTRAORDINARY
13	PETITION DOES NOT GUARANTEE ANY ADDITIONAL
14	CONSIDERATION BY THE BOARD.
15	THE SECOND POINT, AND HAVING TALKED TO
16	STAFF ABOUT THIS, ONE OF THE THINGS IS THAT A LOT OF
17	APPLICANTS HAVE DECIDED THAT THERE'S NO DISADVANTAGE
18	TO GOING AHEAD AND FILING AN EXTRAORDINARY PETITION.
19	BOARD STAFF HAS SPENT AN ENORMOUS AMOUNT OF TIME IN
20	RESPONDING TO EACH OF THESE.
21	ONE CHANGE WE ARE PROPOSING TODAY IS TO
22	RESTRICT BOARD COMMENTS TO THOSE EXTRAORDINARY
23	PETITIONS THAT THEY FEEL HAVE MERIT. SO I THINK WE
24	NEED TO BE CLEAR AS BOARD MEMBERS THAT THE STAFF IS
25	READING ALL THE EXTRAORDINARY PETITIONS. THEY'RE
	42

1	LOOKING AT THE REVIEWS, THEY'RE LOOKING AT THE
2	APPLICATIONS; BUT RATHER THAN JUST SIMPLY HAVE TO
3	RIGOROUSLY, AS WE'VE BEEN DOING, AND I GIVE STAFF AN
4	ENORMOUS AMOUNT OF CREDIT FOR THE DILIGENCE THAT
5	THEY'VE APPLIED IN THIS PROCESS, BUT RATHER THAN
6	HAVE TO WRITE OUT THESE LONG, EXHAUSTIVE
7	POINT-BY-POINT REBUTTALS, THEY'RE ONLY GOING TO
8	RESPOND TO THOSE EXTRAORDINARY PETITIONS THEY FEEL
9	HAVE SOME MERIT IN THEM.
10	SO I THINK AS BOARD MEMBERS WE NEED TO BE
11	CLEAR THAT WHEN WE GET AN EXTRAORDINARY PETITION
12	WITH NO COMMENT FROM STAFF, THAT STAFF DOES NOT
13	SUPPORT THE EXTRAORDINARY PETITION. AND SO UNLESS
14	WE FIND SOME INTRINSIC MERIT IN THEIR ARGUMENTS THAT
15	WE GET, WE OUGHT NOT TO BE BRINGING THESE UP UNLESS
16	WE'RE PREPARED TO ARGUE FOR THEM.
17	MR. TORRES: SO THERE'S AN APPEAL PROCESS
18	IF WE DON'T AGREE WITH HOW THE STAFF HAS DETERMINED?
19	CHAIRMAN SHEEHY: THE PROCESS IS THAT THE
20	MEMBER OF THE BOARD CAN ASK THAT THAT APPLICATION BE
21	CONSI DERED.
22	MR. TORRES: SO IT'S AN APPEAL OF THE
23	STAFF DECISION.
24	CHAIRMAN SHEEHY: IT'S NOT AN APPEAL.
25	IT'S RESPONDING TO THE EXTRAORDINARY PETITION. SO

1	WE CAN HAVE A RESPONSE TO AN EXTRAORDINARY PETITION.
2	I DON'T WANT TO USE THE WORD "APPEAL" IN THE
3	EXTRAORDINARY PETITION PROCESS BECAUSE YOU'RE NOT
4	APPEALING YOUR SCORE OR YOUR RECOMMENDATION FROM THE
5	GRANTS WORKING GROUP. YOU'RE PETITIONING THE BOARD,
6	YOU'RE PROVIDING INFORMATION TO THE BOARD. IF THE
7	BOARD, AS THE DECISION MAKER PER PROP 71, DECIDES TO
8	TAKE UP THAT APPLICATION, CAN LOOK AT THE
9	INFORMATION IN THE EXTRAORDINARY PETITION, THAT'S
10	FULLY WITHIN THE SCOPE OF THE BOARD'S RESPONSIBILITY
11	AND DUTIES. THAT'S THE PREFACE.
12	NOW, WHAT WE'VE KIND OF COME UP WITH, AND
13	I THINK WE MAY NEED SOME DISCUSSION ON SOME POINTS
14	OF THIS, IS MAYBE PROVIDING THE BOARD WITH ANOTHER
15	OPTION BECAUSE I KNOW THAT THERE HAS BEEN THERE
16	HAVE BEEN SITUATIONS WHERE I THINK IT GETS VERY
17	DIFFICULT FOR THE BOARD TO COME TO A CLEAR DECISION.
18	AND WHAT WE'RE CALLING THIS IS AN OPTION FOR
19	RESCORING. THIS IS NOT A REREVIEW OPTION. THIS IS
20	AN OPPORTUNITY FOR THE BOARD, AND THIS IS AN OPTION
21	FOR THE BOARD BESIDES DENYING A GRANT AND APPROVING
22	A GRANT, AND TO BE SPECIFIC, THE WAY IN WHICH THIS
23	WOULD BE WORDED, THIS WOULD BE A DENIAL OF A GRANT
24	PENDING NOT PENDING, BUT UNLESS THE CHAIR OF THE
25	REVIEW SESSION AND ONE OF THE PRIMARY REVIEWERS

1	OFFER A HIGHER SCORE THAN INITIALLY RECOMMENDED FOR
2	THE GRANT, THAT THIS GRANT WOULD BE DENIED.
3	THIS DOES GIVE THE BOARD AN OPPORTUNITY IN
4	SOME CIRCUMSTANCES TO IN MOMENTS OF INDECISION WHEN
5	WE CAN'T GET TO A CLEAR CONSENSUS ON A GRANT TO HAVE
6	WHAT SHOULD BE A RARELY EXERCISED, BUT AVAILABLE
7	OPTION FOR HAVING A GRANT RESCORED. A LOT OF
8	DETAILS IN THE PROCESS IN THE PROPOSAL FOR THE
9	ACTUAL PROCESS. I CAN GO THROUGH IT, BUT I'M HOPING
10	PEOPLE HAVE READ IT. I THINK CHAIRMAN KLEIN HAS A
11	COMMENT HE WANTED TO MAKE.
12	CHAIRMAN KLEIN: IF I COULD JUST COMMENT
13	ON THE POINTS YOU JUST MADE, JEFF, IS THAT THE
14	MESSAGE TO APPLICANTS IS THAT THIS IS A RARE
15	OCCURRENCE WHERE THE BOARD WOULD LOOK TO THIS. THIS
16	IS NOT AN OPEN DOOR. YOU POINTED OUT IN THE SCRIPT
17	HERE THAT IN THE NARRATIVE THAT IF THE SCIENTIFIC
18	STAFF RECOGNIZES THERE'S AN ERROR AND MAKES A
19	RECOMMENDATION TO THE BOARD, THE BOARD RESOLVES THE
20	ISSUE. IF THE BOARD BRINGS UP AN ISSUE WHERE IT IS
21	A PROGRAMMATIC ISSUE, THEY MAKE A DECISION, THEY
22	MOVE ON.
23	THIS IS A VERY, VERY RARE, AS YOU SAID,
24	SITUATION WHERE THE SCIENTIFIC STAFF AND THE BOARD
25	FEEL, AND THE BOARD MAKES A DECISION THAT THEY'D
	45

1	LIKE TO HAVE THIS VERY LIMITED RESCORING OPTION.
2	SO THE BOARD WOULD MAKE A MOTION TO DENY EXCEPT IF
3	IN THAT SITUATION THIS PARTICULAR GRANT HAD A SCORE
4	RAISED IN THIS PROCESS YOU'RE DESCRIBING.
5	MS. SAMUELSON: COULD IT EVER BE USED IN
6	THE SITUATION WHERE THE BOARD WAS INTERESTED IN
7	RESCORING BECAUSE IT THOUGHT THAT IT MIGHT BE
8	APPROPRI ATE?
9	CHAIRMAN SHEEHY: THAT WOULD BE THE
10	CIRCUMSTANCE IN WHICH THE BOARD WOULD USE THIS.
11	MS. SAMUELSON: WHAT I MEAN BY THAT IS
12	THAT IT IS INTERESTED IN A DECISION TO FUND THE
13	GRANT, SO AGAINST THE WORKING GROUP RECOMMENDATION,
14	BUT IT WANTS THE FEEDBACK OF THE WORKING GROUP
15	SCORING PERHAPS WITH SOME PREMISE PRESENTED FOR
16	THEM. IT WANTS INPUT, IN OTHER WORDS.
17	CHAIRMAN SHEEHY: RIGHT. WE DON'T
18	PRECLUDE THE GOAL OF THIS PROCESS IS NOT TO END
19	THE PROGRAMMATIC REVIEW OF GRANTS BY THE BOARD. SO
20	IF THE BOARD HAS A STRONG PROGRAMMATIC BASIS FOR
21	WANTING TO APPROVE A GRANT, THAT SHOULD NOT BE
22	GROUNDS FOR RESCORING. BUT I CAN TELL YOU A
23	CIRCUMSTANCE WHERE I WOULD VISUALIZE THIS IS A GRANT
24	THAT DID NOT GET A FUNDABLE SCORE. BASED ON MY
25	EXPERIENCE AND MY KNOWLEDGE OF HIV, HIV GRANT, I'M

1	READING THE EXTRAORDINARY PETITION AND I SEE
2	SOMETHING THAT I FEEL IS REALLY COMPELLING.
3	THE DISCUSSION AT THE BOARD, OTHER BOARD
4	MEMBERS FEEL HIGHLY UNCOMFORTABLE ABOUT VOTING
5	THROUGH A GRANT WITH THIS SCORE; BUT MAYBE AS A
6	COURTESY TO ME, THEY WOULD ALLOW THIS GRANT TO HAVE
7	THE OPTION FOR RESCORING. WE DON'T ALL HAVE PERFECT
8	KNOWLEDGE ACROSS ALL AREAS OF SCIENCE. CERTAINLY
9	FOR PATIENT ADVOCATES WE HAVE A LOT OF EXPERIENCE
10	WITHIN THE CONTEXT OF THE DISEASES WITH WHICH WE'RE
11	CONFRONTED. CERTAINLY THE WORKING GROUP COVERING A
12	WHOLE HOST OF DISEASES AND CONDITIONS MAY NOT HAVE
13	TOTAL UNDERSTANDING OF ALL ASPECTS OF THE DISEASE.
14	I WOULD EXPECT THIS OPTION TO BE USED VERY
15	RARELY. I WOULD NOT EXPECT IT TO BE USED IN EVERY
16	GRANT ROUND. AND I WOULD EXPECT IT TO ONLY BE USED
17	IN THE MOST EXTRAORDINARY CIRCUMSTANCES.
18	DR. TROUNSON: JEFF, I'M JUST WONDERING
19	ABOUT WHEN YOU ARE TALKING ABOUT RESCORING, YOU
20	REALLY ARE GOING TO HAVE TO PROVIDE SOME ADDITIONAL
21	INFORMATION TO THE REVIEWERS. OTHERWISE,
22	THEORETICALLY AT LEAST, THEY'LL COME UP WITH EXACTLY
23	THE SAME SCORE BECAUSE NOTHING SCIENTIFICALLY HAS
24	CHANGED.
25	WHAT I WAS WONDERING IS THE PROCESS REALLY
	47

1	SHOULD INVOLVE TAKING WHATEVER MATTERS THAT WERE IN
2	SCIENTIFIC DEBATE, IF THEY WERE RAISED, GETTING SOME
3	WORK DONE ON THEM SO THAT THERE IS SOME FURTHER
4	INFORMATION FROM EXPERTS IN THE AREA. AND THEN I
5	KIND OF THINK FOR A RESCORE, IT WOULD BE PROBABLY
6	BEST TO GET THE WHOLE GRANTS REVIEW TEAM BACK TO
7	RESCORE IT BECAUSE ESSENTIALLY YOU'RE GOING TO GIVE
8	THEM SOME REVISED INFORMATION THAT MIGHT BE DERIVED
9	FROM SOME OTHER PLACE BECAUSE THE RESCORE, THE SCORE
10	IS A SCIENTIFIC SCORE. SO I THINK YOU HAVE TO
11	ACTUALLY GO TO SOME CHANGE IN THE SCIENCE, WHETHER
12	THEY REALLY GOT IT CORRECTLY IN THE FIRST PLACE OR
13	IT WAS A DIFFERENT PERSPECTIVE ON SOME OF THE
14	SCIENTIFIC ISSUES THAT WERE RAISED.
15	SO I WONDERED IF YOU'RE GOING TO RESCORE,
16	YOU PROBABLY HAVE TO GET THE INFORMATION, DO SOME
17	ANALYSIS ON IT, GET IT BACK TO THE REVIEWERS, AND
18	THEN ASK THEM TO RELOOK AT IT IN THE LIGHT OF THE
19	NEW INFORMATION.
20	CHAIRMAN SHEEHY: I GUESS I'M CONFUSED
21	HERE BECAUSE I DISCUSSED THIS PROCESS WITH STAFF
22	BEFORE WE BROUGHT IT TO THE BOARD, AND EXPLICITLY
23	THE REQUEST WAS NOT TO INVOLVE THE ENTIRE WORKING
24	GROUP. SO IF STAFF IS IN AGREEMENT WITH THE
25	PRESIDENT, I DON'T KNOW WHAT KIND OF PROCESS WE HAVE

1	FOR RESOLVING THESE TYPES OF ISSUES.
2	CHAIRMAN KLEIN: LET ME ASK THIS QUESTION,
3	JEFF. THIS IS BOB KLEIN. IS IT POSSIBLE WE HAVE
4	TWO DIFFERENT FACT PATTERNS? ONE, THERE'S A NATURE
5	ARTICLE THAT COMES OUT THAT'S, YOU KNOW, A
6	BREAKTHROUGH ARTICLE THAT HAPPENS TO VALIDATE THIS
7	RIGHT BEFORE THE BOARD MEETS. AND SO I'D ASK DR.
8	TROUNSON, IN THAT PARTICULAR CASE MAYBE THE
9	SCIENTIFIC STAFF IS COMFORTABLE WITH, GIVEN THE
10	BLATANT NATURE OF THE CHANGE, JUST HAVING A LIMITED
11	CATEGORY.
12	I THINK WHAT JEFF IS REFERRING TO IS PRIOR
13	TO DISCUSSIONS THAT MAYBE EVEN OCCURRED AT THE BOARD
14	LEVEL WHERE THERE'S CONCERN ON CONSERVING THE TIME
15	OF THE GRANTS REVIEW WORKING GROUP, AND IS IT
16	POSSIBLE THAT WE COULD HAVE A DICHOTOMOUS CHOICE
17	HERE, THAT IF IT WAS A CLEAR PUBLICATION OR
18	SOMETHING THAT CAME OUT WHERE THEY WANTED A
19	RESCORING OF IT IN LIGHT OF THIS PUBLICATION TO SEE
20	IF IT ACTUALLY DIRECTLY RELATED TO THIS GRANT OR
21	NOT, THAT YOU COULD HAVE A MORE LIMITED CHOICE OF
22	JUST GOING TO A COUPLE OF PEOPLE. AND IF IT WERE A
23	MORE COMPLICATED, BROADER ISSUE, THAT MAYBE YOU
24	COULD USE THE FULL REVIEW BOARD, BUT TRY AND,
25	THEREFORE, ACCOMPLISH JEFF'S GOAL OF RESPONDING TO

1	THE STAFF'S GENERAL CONCERN OF NOT BURDENING THE
2	WHOLE BOARD WITH A REVIEW.
3	DR. TROUNSON: I DIDN'T GET ANY DISCUSSION
4	OF THIS ISSUE PRIOR TO STAFF, SO IT'S MY OWN VIEW.
5	SO I'M NOT SUGGESTING THAT I'M REPRESENTING STAFF'S
6	VIEW. IT'S JUST THAT IF YOU'RE GOING TO RESCORE,
7	YOU PROBABLY HAVE SOME BASIS TO RESCORE. OTHERWISE
8	I WOULD JUST COME UP WITH THE SAME SCORE, IF I WAS A
9	REVI EWER.
10	CHAIRMAN SHEEHY: THAT'S THE EXPECTATION,
11	AND THE INFORMATION WILL BE THAT THEY PROVIDED
12	PUBLICLY TO THE EXTRAORDINARY PETITION PROCESS, AND
13	IT'S JUST AN OPTION FOR THE BOARD. THE IDEA IS NOT
14	TO PROVIDE A PATH TO REREVIEW. I PERSONALLY HAVE
15	TENDED TO AGREE WITH STAFF, THAT REREVIEW IS NOT
16	PART OF OUR PROCESS AT LEAST AT THIS TIME. WE MAY
17	WANT TO TAKE IT UP LATER. HOWEVER, I THINK THE
18	OPPORTUNITY YOU KNOW, WE'VE BEEN IN SITUATIONS
19	WHERE WE'VE BEEN AT
20	MS. SAMUELSON: THERE HAVE BEEN CHANGES IN
21	CI RCUMSTANCES.
22	CHAIRMAN SHEEHY: NOT ABLE TO REALLY
23	COME TO A CONSENSUS. AND I THINK THAT OUR DECISIONS
24	AT THAT POINT GET REALLY ARBITRARY. AND I DON'T
25	THINK IT HAPPENS THAT OFTEN. BUT CERTAINLY, YOU
	F.0

1	KNOW, THERE ARE TIMES WHEN THERE'S AN EXTRAORDINARY
2	AMOUNT OF PRESSURE ON US AS BOARD MEMBERS TO MAKE
3	DECISIONS ONE WAY OR THE OTHER. I THINK THAT THIS
4	JUST GIVES US ANOTHER OPTION TO MAKE THE DECISION.
5	OTHER BOARD MEMBERS WANT TO MAKE COMMENTS?
6	DR. BRYANT: I WOULD LIKE TO MAKE A
7	COMMENT AT SOME POINT AS A MEMBER OF THE PUBLIC.
8	THIS IS SUE.
9	MS. SAMUELSON: GO AHEAD, SUE.
10	DR. BRYANT: I WOULD SAY THERE ARE TWO
11	THINGS. THERE'S THE FAIRNESS OF THE PROCESS, BUT
12	THERE'S PROTECTING THE GRANTS REVIEW COMMITTEE FROM
13	HAVING EXCESSIVE WORKLOAD. I THINK YOU HAVE TO HAVE
14	VERY TIGHT GUIDELINES. AND I THINK PRODUCING
15	EVIDENCE THAT HAS APPEARED IN PRESS THAT DIRECTLY
16	REFUTES THE DECISION IS ABOUT AS FAR AS YOU WANT TO
17	GO BECAUSE IF YOU LEAVE IT MORE BROAD THAN THAT,
18	ANYBODY WHO GETS TURNED DOWN COULD COME BACK WITH
19	ANYTHING. IT WOULD JUST LIKE OPEN IT UP FOR
20	COMPLETE CHAOS IN A WAY IF YOU DON'T MAKE IT REALLY
21	SPECI FI C.
22	SO THAT'S MY OPINION ON THAT, BUT I'M
23	WILLING TO LISTEN TO OTHER THINGS. I THINK
24	EVERYBODY I THINK THE OPPORTUNITY FOR A REREVIEW
25	UNDER CIRCUMSTANCES WHERE THE DECISION CAN CLEARLY
	F.1

1	BE SHOWN TO BE MISGUIDED AND UNINFORMED BECAUSE THE
2	INFORMATION WASN'T THERE OR THE PERSON DIDN'T KNOW
3	ABOUT IT, DOESN'T MATTER WHETHER IT'S RECENTLY
4	PUBLISHED OR PUBLISHED AT AN EARLIER TIME, IT'S NOT
5	NECESSARILY THE CASE THAT EVERYBODY KNOWS EVERYTHING
6	ALL THE TIME. I THINK THAT WOULD BE A CAUSE FOR
7	HAVING A REREVIEW.
8	MR. ROTH: GET ME IN WHEN YOU CAN, JEFF.
9	DR. STEWARD: I'D LIKE TO SAY SOMETHING
10	TOO WHEN I SHOW UP IN THE ORDER HERE.
11	CHAIRMAN SHEEHY: WE'LL DO JOAN, DUANE,
12	AND OS RIGHT AFTER GIL MAKES A COMMENT.
13	MS. SAMUELSON: IT SEEMS TO ME THERE HAVE
14	BEEN SITUATIONS WHERE THE BOARD HAS FOUND EITHER
15	FACTUAL ERROR OR SOME KIND OF THAT THEIR
16	ASSESSMENT OF THE GRANT IS INCONSISTENT WITH THE
17	SCORE, AND THERE'S BEEN CURIOSITY ABOUT WHY THERE IS
18	THAT INCONSISTENCY. IT WOULD BE NICE TO HAVE THAT
19	I NPUT.
20	CHAIRMAN SHEEHY: GIL HAD A COMMENT.
21	DR. SAMBRANO: I HAVE JUST A COUPLE OF
22	POINTS. I THINK, IN GENERAL, I THINK STAFF
23	CERTAINLY AGREES WITH THE IDEA OF HAVING AND
24	CREATING AN OPTION THAT'S AVAILABLE TO THE BOARD. I
25	THINK THAT WE CAN IMAGINE, HOWEVER, A VARIETY OF

1	SITUATIONS WHERE SOME MIGHT BE EASILY RESOLVED BY
2	SIMPLY TAKING MORE TIME AND HAVING STAFF LOOK INTO A
3	SITUATION AND RESOLVING IT THERE.
4	ON THE OTHER EXTREME, IT MIGHT REQUIRE
5	ADDITIONAL EXPERTISE IN ORDER TO RESOLVE IT IF IT'S
6	A SCIENTIFIC ISSUE THAT NEEDS TO BE MORE FULLY
7	VETTED. I THINK THE POTENTIAL DANGER OF HAVING THE
8	ENTIRE GRANTS WORKING GROUP INVOLVED WOULD TEND TO
9	IMPLY THAT YOU'RE NOW ENGAGED IN A COMPLETE REREVIEW
10	OF AN APPLICATION WHICH WE REALLY WANT TO TRY TO
11	AVOI D.
12	THE OTHER THING I WANTED TO POINT OUT IS
13	THAT IN TERMS OF WHAT TRIGGERS THIS KIND OF EVENT,
14	WE ALREADY HAVE A POLICY IN PLACE THAT ALLOWS
15	APPLICANTS TO SUBMIT SUPPLEMENTAL INFORMATION AFTER
16	THE APPLICATION IS IN. AND IT'S DESIGNED SO THAT
17	THE GRANTS WORKING GROUP HAS THE OPPORTUNITY TO
18	COMMENT ON IT BEFORE THE REVIEW AND CAN INCORPORATE
19	THAT NEW INFORMATION INTO THEIR SCORE AND INTO THEIR
20	ASSESSMENT.
21	AND SO I WOULD WANT TO BE CAREFUL ABOUT
22	THE TYPE OF ALLOWANCE THAT'S MADE IN TERMS OF NEW
23	DATA OR INFORMATION BECAUSE THAT ITSELF MIGHT ALSO
24	TRIGGER A NEED FOR A REREVIEW AS OPPOSED TO LOOKING
25	AT SPECIFIC INFORMATION OR A SCIENTIFIC QUESTION

1	THAT JUST NEEDS TO BE CLARIFIED TO HELP THE BOARD
2	MAKE A DECISION.
3	CHAIRMAN SHEEHY: DUANE, I THINK YOU WERE
4	UP NEXT.
5	MR. ROTH: YES. I'M SORRY ABOUT THIS. I
6	HAVE THREE CELL PHONES AND THEY'RE ALL GOING OUT AT
7	THE SAME TIME.
8	SO I WANT TO ALIGN WITH THE COMMENTS ABOUT
9	REREVIEW AND NEW INFORMATION. I THINK YOU HAVE TO
10	HAVE A REALLY IMPEACHABLE PROOF STANDARD THERE.
11	OTHERWISE EVERYBODY HAS NEW INFORMATION AND THEY'LL
12	BRING IT TO YOU. AND WHILE THIS IS CRAFTED TO BE
13	VERY NARROW, MY CONCERN WILL BE, LIKE OUR OTHER
14	OPTIONS FOR PETITIONS AND CONFLICT OF INTEREST, IT
15	WILL GROW THE FIRST TIME WE APPROVE ONE OF THESE
16	UNDER THIS PROCEDURE. SO WHATEVER WE DO, LET'S MAKE
17	SURE THAT WE'RE AS TIGHT AS WE POSSIBLY CAN BE.
18	AND I'M PARTICULARLY BOTHERED BY NEW
19	INFORMATION. THAT IMPLIES TO ME THAT YOU REALLY
20	DON'T HAVE A LEVEL PLAYING FIELD BECAUSE, AS I SAID,
21	THERE'S CONSTANT UPDATES TO THESE SCIENTIFIC
22	PROGRESSES. AND THIS WOULD REALLY SEEM TO ME TO ADD
23	ANOTHER COMPLEXITY.
24	FINALLY, THE REVIEWERS, I CAUGHT THE SAME
25	THING, IF YOU'VE GOT THE SAME PEOPLE REVIEWING THE
	E 4

1	SAME INFORMATION, WHICH IS REALLY WHAT IT SHOULD BE,
2	THEY'RE PROBABLY GOING TO COME TO THE SAME IDEA. SO
3	MAYBE AN OUTSIDE REVIEW BY A DIFFERENT GROUP TO SEE
4	IF THERE'S VALIDITY MIGHT BE IMPORTANT. THANKS.
5	CHAIRMAN SHEEHY: AND THEN OS.
6	DR. STEWARD: THANKS. SO I JUST HAVE TO
7	SHARE THE CONCERNS THAT BOTH SUE STARTED WITH AND
8	DUANE RAISED. I THINK THIS IS A REALLY SLIPPERY
9	SLOPE, AND I GUESS I AM CONCERNED ABOUT THE WHOLE
10	PROCESS IN GENERAL. I THINK THIS CAN JUST EXPLODE.
11	HAVING SAID THAT, THERE ARE REALLY TWO KEY
12	THINGS THAT I'D LIKE TO RAISE. FIRST OF ALL IS THE
13	QUESTION OF WHETHER THE BOARD REALLY ALREADY HAS
14	THIS OPTION. AND JUST REALLY THINKING ABOUT WHAT
15	GIL SAID, WE CAN IMAGINE A MULTITUDE OF DIFFERENT
16	SCENARIOS HERE THAT THE BOARD MAY WANT TO CONSIDER.
17	AND I KIND OF THINK THAT THE BOARD REALLY ALREADY
18	HAS THE ABILITY TO REQUEST A REREVIEW, A REANALYSIS,
19	WHATEVER, AT ITS DISCRETION. WE DON'T NEED A
20	POLI CY.
21	NO. 2, AND THIS IS A MORE FUNDAMENTAL
22	THING, AND I'VE BEEN THINKING ABOUT THIS IN TERMS OF
23	THIS WHOLE ISSUE OF EXTRAORDINARY PETITIONS. THE
24	THING THAT WE MOST OFTEN RUN INTO IS AN INVESTIGATOR
25	WHO, FIRST OF ALL, IDENTIFIES THEMSELVES, WHICH IS

1	REALLY, I GUESS, I THINK ONE OF THE FUNDAMENTAL
2	PROBLEMS WITH THIS PROCESS, BECAUSE IF THIS IS
3	SOMEBODY WE ALL KNOW, WE SAY, "OH, WELL, THIS PERSON
4	DESERVES SOME REALLY EXTRA ATTENTION." AND IF IT'S
5	NOT SOMEBODY WE KNOW, THEN MAYBE WE PAY LESS
6	ATTENTION TO IT. IT REALLY IS A FUNDAMENTAL, I
7	GUESS, UNLEVELING OF THE PLAYING FIELD.
8	AND THE PROBLEM THAT WE MOST OFTEN RUN
9	INTO IS THAT WHOEVER SAYS, YOU KNOW, THE REVIEWER
10	MISSED THIS OR THERE'S A MISTAKE OR WHATEVER, AND WE
11	HAVE IN FRONT OF US THE LETTER FROM THE
12	INVESTIGATOR, BUT WE'RE STILL UNABLE TO LOOK AT THE
13	GRANT ITSELF OR THE COMMENTS OF THE REVIEW PANEL.
14	SO MY SPECIFIC PROPOSAL THAT NOW I'M GOING
15	TO MAKE FOR ALL OF THE EXTRAORDINARY PETITIONS IS
16	THAT IF AN INVESTIGATOR WANTS TO MAKE AN
17	EXTRAORDINARY PETITION, THEY SHOULD VOLUNTEER
18	THEMSELVES TO PROVIDE THE ICOC WITH A COPY OF THE
19	ORIGINAL PROPOSAL AND A COPY OF THE REVIEW. IN
20	OTHER WORDS, LET'S GET ALL THE ISSUES OUT ON THE
21	TABLE FOR OUR CONSIDERATION.
22	CHAIRMAN KLEIN: CAN I MAKE A LEGAL
23	COMMENT HERE?
24	CHAIRMAN SHEEHY: OKAY. THE CHAIR HAS A
25	LEGAL.

1	CHAIRMAN KLEIN: IF WE NEED ADDITIONAL
2	SUPPORT OF CALLING COUNSEL, BUT WE SACRIFICE ALL THE
3	PROPRIETARY INFORMATION IF IT'S SUPPLIED TO ALL THE
4	BOARD MEMBERS AS THE FULL APPLICATION.
5	DR. STEWARD: BOB, I'M SORRY. I HAVE BEEN
6	THINKING ABOUT THIS AND I FORGOT TO SAY THAT. THERE
7	CAN BE TRULY PROPRIETARY INFORMATION IN THE PROPOSAL
8	THAT COULD BE REDACTED. BUT, IN FACT, 99 PERCENT OF
9	THE PROPOSAL AND CERTAINLY THE PART THAT THE
10	REVIEWER OR THE APPLICANT IS CHALLENGING ALREADY
11	IS PUBLIC. SO BASICALLY THE APPLICANT CAN SAY I'D
12	LIKE PAGE 8, LINES 15 THROUGH 35 REDACTED FOR
13	PROPRIETARY REASONS. EVERYTHING ELSE GOES PUBLIC.
14	CHAIRMAN SHEEHY: SO ARE YOU MAKING A
15	MOTI ON?
16	DR. STEWARD: I WILL. LET'S ACTUALLY
17	START WITH POINT NO. 1. POINT NO. 1 IS DON'T WE AS
18	THE BOARD ALREADY HAVE THE CAPACITY TO REQUEST AN
19	EXTRAORDINARY ANYTHING WE WANT IN TERMS OF REREVIEW,
20	RECONSIDERATION, WHATEVER? IF SO, THEN I DON'T
21	THINK A FORMAL POLICY IS NECESSARY.
22	CHAIRMAN SHEEHY: I WOULD SAY THAT WE
23	POSSIBLY DO. IT'S NOT PART OF OUR NORMAL PROCESS.
24	WE DON'T HAVE THE ABILITY TO DO A TWO-PERSON REVIEW.
25	THAT DOESN'T EXIT. LET ME JUST MAKE A POINT ABOUT

1	THI S.
2	I KIND OF WANT US TO GET AWAY FROM
3	THINKING ABOUT THE FAIRNESS OF THE PROCESS. THIS
4	HAS KIND OF COME UP A COUPLE OF TIMES. AND THIS IS
5	A NUANCE, AND I'VE GOTTEN IN TROUBLE FOR TRYING TO
6	ADDRESS THIS, BUT I THINK JOAN WILL PROBABLY AGREE
7	WITH ME ON THIS. WHAT IS IMPORTANT IS THAT WE FUND
8	THE BEST SCIENCE AND THAT WE DON'T RUN A GREAT HORSE
9	RACE. WE RUN A HORSE RACE BECAUSE THAT'S HOW YOU
10	DETERMINE WHAT THE BEST SCIENCE IS, BUT EVERY NOW
11	AND THEN THERE'S A GOOD HORSE THAT DIDN'T MAKE THE
12	FINISH LINE. AND WE'VE TAKEN ADVANTAGE OF THAT
13	BEFORE. THE ABOUDI GRANT IS A GREAT EXAMPLE OF A
14	GOOD HORSE THAT DIDN'T MAKE THE FINISH LINE.
15	AS A PATIENT ADVOCATE, I'M LESS
16	INTERESTED I DON'T WANT TO FUND BAD SCIENCE. SO
17	THAT'S MY PRIORITY OFF THE TOP. I DON'T WANT TO
18	FUND BAD SCIENCE. BUT IF SOMETHING EMERGES THAT
19	SHOWS THAT THIS WAS GOOD SCIENCE, AND THE ABOUDI
20	CASE IS A GREAT EXAMPLE, I DON'T WANT TO SAY, WELL,
21	YOU KNOW, YOU LOST THE RACE. YOU'RE NOT GOING TO
22	GET FUNDED TILL TWO YEARS FROM NOW WHEN WE COME BACK
23	TO THIS GRANT ROUND. PEOPLE WILL HAVE DIED WITHOUT
24	A SUCCESSFUL THERAPY.
25	SO WHAT I REALLY WANT TO FOCUS ON, AT

1	LEAST PERSONALLY, IS CAPTURING GOOD SCIENCE. AND IF
2	THERE IS SOME INFORMATION RELEVANT TO A GRANT THAT
3	COMES UP IN THE CONTEXT OF AN EXTRAORDINARY
4	PETITION, I WOULD LIKE TO FIGURE OUT SOMEHOW TO DO
5	THAT. I KNOW THAT A LOT OF BOARD MEMBERS DON'T FEEL
6	COMFORTABLE MAKING DECISIONS ON THESE GRANTS
7	SOMETIMES. I DON'T THINK REREVIEW IS AN OPTION WE
8	OUGHT TO GO INTO, BUT I'M OPEN TO ANY IDEA. THIS
9	WAS JUST ONE IDEA, BUT WHAT WE HAVE RIGHT NOW IS A
10	BROKEN SYSTEM. AND I THINK IT'S INCUMBENT ON US TO
11	SET THE CONTOURS FOR THE SYSTEM.
12	IF WE DON'T ALLOW A LOT OF RESCORING, IT'S
13	NOT GOING TO BE ADVANTAGEOUS TO PEOPLE. THEY CAN'T
14	COME IN AND ASK FOR A RESCORE. THAT'S NOT PART OF
15	THE EXTRAORDINARY PETITION PROCESS. REMEMBER THE
16	RESCORING IS DENIAL. I THINK THE CRITICISM THAT'S
17	BEEN MADE IS THAT THE SAME REVIEWERS ARE HIGHLY
18	LIKELY TO GIVE IT THE SAME SCORE. YES. IT'S ALMOST
19	WHENEVER WE PUT IN THESE CONTROL FEATURES, THERE'S
20	RESISTANCE. SO A FEATURE WHERE THE BOARD DOESN'T
21	LOOK AT AN EXTRAORDINARY PETITION UNLESS AN
22	INDIVIDUAL MEMBER THINKS IT HAS MERIT HAS KIND OF
23	DEGRADED EVEN THOUGH THAT WAS ONE OF OUR BIG CONTROL
24	POINTS, THAT PEOPLE WOULD RECOGNIZE THAT IT DIDN'T
25	AVAIL THEM IN MOST INSTANCES TO DO AN EXTRAORDINARY

ı	PETITION. INSTEAD, WE CONSIDER EVERY ONE, SO NOW
2	IT'S BECOME A FEATURE OF GAMESMANSHIP OR
3	GRANTSMANSHIP ALWAYS TO DO AN EXTRAORDINARY
4	PETI TI ON.
5	IF WE ASSERT SOME DISCIPLINE AS A BOARD
6	AND ONLY EXERCISE THIS OPTION WHEN WE FEEL LIKE
7	THERE'S COMPELLING EVIDENCE, WITH THE UNDERSTANDING
8	THAT FOR SOME GRANTEES THEY MAY HAVE HAD A BETTER
9	SHOT UP AND DOWN ON THEIR GRANT, THIS ACTUALLY MAY
10	DISADVANTAGE SOME GRANTS BECAUSE THE BOARD IS GOING
11	TO PASS ON ACTUALLY CONSIDERING THEM. WITH THE
12	UNDERSTANDING THAT THE SAME REVIEWER WHO GAVE YOU A
13	65 IS STILL GOING TO GIVE YOU A 65 AND THAT'S IT, I
14	THINK WE DON'T WE'RE NOT TRYING TO CREATE MORE
15	OPEN DOORS; BUT FOR THE REALLY GOOD PIECE OF
16	INFORMATION THAT'S REALLY COMPELLING TO A BOARD
17	MEMBER THAT MIGHT BE COMPELLING TO A REVIEW WHO HAS
18	ALREADY LOOKED AT THE GRANT, WHO KNOWS THE GRANT,
19	WHO CAN TAKE A LITTLE BIT OF TIME TO LOOK AT THIS
20	PIECE OF INFORMATION AND SAY, NAH, DOESN'T PERSUADE
21	ME, OR SAY, IF I THOUGHT OF THAT, I'D HAVE GIVEN
22	THIS AN 80, THAT'S WHAT WE'RE TRYING TO ACCOMPLISH.
23	BUT WE'RE NOT TRYING TO CREATE A BIG OPEN
24	DOOR; BUT IF THERE ARE OTHER OPTIONS OUT THERE, I'M
25	WILLING TO HEAR THEM. ART HAS A COMMENT AND I THINK
	60

1	JOAN.
2	DR. PIZZO: PHIL WOULD LIKE TO MAKE A
3	COMMENT TOO.
4	MR. TORRES: QUICKLY. I AGREE WITH WHAT
5	ALAN SET OUT AT THE OUTSET, AND THAT IS THAT YOU'RE
6	GOING TO PROBABLY GET THE SAME SCORE IF YOU GO BACK
7	TO THE REVIEWERS WHO REVIEWED THE GRANT INITIALLY.
8	I ALSO LIKE OSSIE AND DUANE'S PERSPECTIVE, AND THAT
9	IS, WELL, IF THAT'S THE CASE, WHAT ABOUT AN OUTSIDE
10	REVI EW.
11	SO MY QUESTION IS WHAT TRIGGERS THAT AND
12	IS THAT PRACTICAL? I THINK BEST TO HEAR FROM DR.
13	TROUNSON ON THAT.
14	MS. KING: BEFORE WE GO ON TO OTHER
15	COMMENTS, I JUST WANT TO POINT OUT TO MR. SHEEHY
16	THAT IT'S ACTUALLY NOON RIGHT NOW. WE MAY START TO
17	LOSE PEOPLE. YOU NEED TO THINK ABOUT IN THE NEXT
18	COUPLE MINUTES AFTER THESE COMMENTS WHAT WE WANT TO
19	DO WITH THE RECOMMENDATIONS VIS-A-VIS THE BOARD.
20	MR. TORRES: OSSIE, YOU CAN CHIME IN AS
21	WELL.
22	DR. TROUNSON: YOU CAN USE THE EXAMPLE OF
23	THE ABOUDI GRANT BECAUSE IT WAS RAISED BY JEFF, THAT
24	WE WENT OUT TO A WHOLE LIST OF PEOPLE THAT I THOUGHT
25	WAS EXPERT IN THE AREA, AND WE GOT A DIFFERENT VIEW

1	TO ONE OF THE PRIMARY CONCLUSIONS OF THE REVIEWERS.
2	I FELT THAT THAT INFORMATION NEEDED TO BE BROUGHT TO
3	THE BOARD BECAUSE I THOUGHT IT WAS WRONG. I
4	ACTUALLY THOUGHT IT WAS WRONG WHEN I LISTENED TO THE
5	REVIEW, SO I WENT TO EXPLORE THAT EVEN BEFORE WE GOT
6	THE PETITION. SO YOU DO NEED A BIT OF TIME IF
7	YOU'RE GOING TO GET HOLD OF AN EXTERNAL REVIEWER AND
8	DO ALL OF THAT SORT OF THING. SO THAT'S REALLY
9	QUITE DIFFICULT UNLESS THERE'S ENOUGH SPACE BETWEEN
10	THE TIME YOU RECEIVE A PETITION AND YOU CAN ACTUALLY
11	ADDRESS THAT FOR THE BOARD. SO SORT OF FIVE DAYS
12	REALLY STRETCHES US TO DO THAT. AND IF IT'S LESS
13	THAN THAT, IT'S IMPOSSIBLE, AS JEFF SAID.
14	I THINK IT DEPENDS ON WHAT THE ISSUE IS,
15	AND I THINK SOMETIMES YOU MIGHT NEED TO GET A
16	DIFFERENT KIND OF PERSON TO DO THAT BECAUSE THE
17	EXPERTISE MAY NOT BE DWELLING IN THE ORIGINAL
18	REVIEWER. IT MIGHT BE SOMETHING THAT'S OUT OF THE
19	BOX. IT'S NOT EXACTLY. BUT ON THE OTHER HAND,
20	THOSE ARE THE PEOPLE THAT HAVE READ THROUGH, THEY' VE
21	LISTENED TO ALL THE ARGUMENT, AND THEY'VE GOT A
22	KNOWLEDGE OF THAT PROJECT WITH RESPECT TO THE OTHER
23	PROJECTS. THE PEOPLE WHO HAVE BEEN THROUGH THE
24	REVIEW HAVE BEEN WELL SCHOOLED GENERALLY. I'M JUST
25	STRUGGLING TO TRY AND FIND MYSELF WHAT'S THE BEST

1	THING TO DO. I THINK IT'S A COMBINATION OF MAYBE
2	ALL OF THESE THINGS, AND PROBABLY NOT EVERY ONE FITS
3	EXACTLY INTO THE SAME CATEGORY, THAT WE MIGHT NEED
4	SOME FLEXIBILITY TO ADDRESS THIS.
5	I UNDERSTAND I BETTER UNDERSTAND WHAT
6	JEFF'S ISSUE IS, AND I BETTER UNDERSTAND ACTUALLY
7	WHAT GIL'S POINT IS, AND I HAVEN'T HAD THIS
8	OPPORTUNITY OF DISCUSSION BEFORE TODAY. I'M SORRY.
9	WE SHOULD TRY AND FIX THAT. BUT I THINK WE NEED A
10	LITTLE BIT OF FLEXIBILITY, AND IT'S SOMETHING WHICH
11	THEN IS CONCERNING AND IS VERY DEEP AND MIGHT
12	ACTUALLY REQUIRE A WHOLE REREVIEW IF IT'S DEEP AND
13	IT HAS TO BE PLOWED THROUGH RIGHT AGAIN. I THINK
14	THERE'S GOING TO BE VARIANCE; BUT IF IT'S USED
15	SPARINGLY AND IT'S USED VERY SPARINGLY, I THINK IT
16	CAN BE HANDLED IN A WAY THAT YOU GET THE REQUIRED
17	OUTCOME. IF IT BECOMES A THING WHICH PEOPLE USE
18	FREQUENTLY, THEN I THINK IT'S GOING TO BE AN
19	ENORMOUS BURDEN FOR US ALL.
20	MS. SAMUELSON: I THINK BACK TO WHAT WE'RE
21	TRYING TO ACCOMPLISH, WHICH I THINK IS TO IMPROVE
22	UPON THE EXTRAORDINARY PETITION PROCESS THAT'S JUST
23	BEING IMPLEMENTED NOW. AND IT MAY BE THAT IT'S I
24	DON'T SEE IT AS A BROKEN SYSTEM EXACTLY. THERE ARE
25	CONCERNS ABOUT IT. BUT MAYBE IT'S LIKE DEMOCRACY.

1	WE'RE NOT NUTS ABOUT IT, BUT IT'S THE BEST WE'VE
2	GOT. AND MAYBE SOMETHING LIKE OS' SUGGESTION MIGHT
3	ASSIST THE BOARD IN FEELING IT'S GOT THE FAIREST
4	POSSIBLE SYSTEM IT CAN HAVE UNDER THE CIRCUMSTANCES
5	AND IT HAS THE INFORMATION THAT CAN BE MOST USEFUL
6	TO COMING TO A CONCLUSION WHERE IT MAY BE, AND WE'VE
7	HAD EXAMPLES OF IT, WHERE THERE HAVE BEEN SITUATIONS
8	WHERE THE BOARD FOUND THAT THE SCORES JUST REALLY
9	DIDN'T REFLECT ACCURATELY WHAT IT WAS SEEING IN THE
10	INFORMATION THAT WAS BEING GIVEN, AND THAT AT TIMES
11	THERE WERE FACTUAL ERRORS.
12	SO WE WANT THE BOARD TO HAVE THE BENEFIT
13	OF THAT. AND I HAVE FOUND THE CRITIQUES TO BE THE
14	MOST USEFUL DOCUMENTS MYSELF. AND IF THOSE COULD BE
15	FURNISHED AS WELL AS WHATEVER OTHERS, OS OR OTHERS
16	THINK IS APPROPRIATE.
17	DR. PIZZO: YOU KNOW, I THINK, AS OTHERS
18	ARE STATING, I ALSO AGREE, EVEN THOUGH IT MIGHT BE
19	MORE CUMBERSOME, THAT OS' RECOMMENDATION MAKES
20	SENSE. AND THERE'S ONE OTHER VARIABLE THAT I
21	HAVEN'T HEARD, BUT WHICH HAS CERTAINLY COME TO MY
22	OWN ATTENTION WHEN I'M AT THE MEETINGS AND THESE
23	THINGS ARE BEING DISCUSSED, WHICH IS THE EMOTIONAL
24	OVERTONE THAT UNDERSTANDABLY TAKES PLACE. I HAVE
25	WATCHED AND WE'VE ALL WITNESSED WHEN SOMEONE SPEAKS

1	WITH DEEP CONCERN AND PASSION, PARTICULARLY ABOUT A
2	MEMBER OF THEIR OWN FAMILY, THAT UNDERSTANDABLY WE
3	RESPOND TO THAT AND WE'RE RESPONDING IN THE MOMENT.
4	AND I THINK THERE'S A BENEFIT TO LISTENING IN THE
5	MOMENT, BUT THEN HAVING AN OPPORTUNITY TO BE SURE
6	THAT WE'RE REACTING WITH THE MOST CRITICAL DATA THAT
7	WE CAN.
8	CHAIRMAN SHEEHY: TO BE PERFECTLY HONEST,
9	DR. PIZZO, THAT WAS ONE OF THE DRIVING FORCES FOR
10	THIS POLICY BECAUSE A LOT OF TIMES I FIND MYSELF
11	COMPELLED BY EMOTION AND I'VE LOST THE SCIENCE. SO
12	MY THOUGHT WAS THAT THIS GAVE ME AN OPTION AS A
13	BOARD MEMBER WITH REALLY THE APPLICATION
14	FUNDAMENTALLY DENIED UNLESS IT WAS COMPELLING TO THE
15	CHAIR OF THE REVIEW GROUP AND ONE OF THE PRIMARY
16	REVIEWERS THAT SOME OF THE NEW INFORMATION, WHICH
17	HAS BEEN PRESENTED IN THESE EMOTIONAL ATMOSPHERES,
18	IF IT'S COMPELLING TO A REVIEWER, FAIRLY OBJECTIVELY
19	IN AN ATMOSPHERE WHERE THERE'S NO EMOTION, THEN I'M
20	HAPPY TO HAVE THE GRANT COME BACK AND CONSIDER IT
21	AND FUND IT. BUT THIS WAS A WAY TO ACTUALLY
22	DR. PIZZO: FAIR ENOUGH.
23	CHAIRMAN SHEEHY: GIVE THE BOARD A WAY
24	TO DEAL WITH THESE WITH A LITTLE LESS EMOTION, SO
25	RETHINKING THAT THERE MIGHT HAVE BEEN VALUABLE
	/ 5

1	INFORMATION IN THERE. THAT WAS ONE OF THE DRIVERS
2	FOR THIS.
3	DR. PIZZO: THANKS FOR THAT, JEFF.
4	CHAIRMAN SHEEHY: I ALSO DIDN'T WANT TO
5	MAKE THAT THE ONLY REASON FOR THIS PROPOSAL.
6	DR. PIZZO: NO, IT'S NOT. OF COURSE, IT
7	SHOULD NEVER BE, BUT IT CERTAINLY HAD AN IMPACT.
8	CHAIRMAN SHEEHY: SO, AGAIN, AS YOU THINK
9	ABOUT IT AS A BOARD MEMBER, YOU CAN SAY I'M VERY
10	SYMPATHETIC TO WHAT YOU'RE TALKING ABOUT. LET'S SEE
11	WHAT THE REVIEWERS CHANGE. WE HAVE YOUR PETITION,
12	WE HAVE ALL THE INFORMATION YOU PROVIDED US. WE'LL
13	SEND IT ON AND IF THEY AGREE. THAT'S WHERE I WAS
14	GOI NG.
15	BUT I WAS ALSO GOING TO THAT OTHER ASPECT
16	WHERE I AS A PATIENT ADVOCATE SOMETIMES WILL HAVE
17	AND OTHER BOARD MEMBERS, BASED ON THEIR SPECIFIC
18	SCIENTIFIC EXPERIENCE, MAY FEEL LIKE THAT THEY READ
19	THE PETITION, THEY MAY FEEL LIKE THEY HAVE ENOUGH
20	INFORMATION AND OTHER BOARD MEMBERS, RATHER THAN GET
21	SO CONTENTIOUS, WHY DON'T YOU SUPPORT MY GRANT, TO
22	SAY, WELL, LET'S RESCORE IT. IF THE INFORMATION
23	REALLY IS VALUABLE SCIENTIFICALLY, THEN THE
24	REVIEWERS WILL RECOGNIZE IT BECAUSE WE HAVE
25	OUTSTANDING REVIEWERS AND THEY KNOW THE SCIENCE, AND
	66

1	IT WOULDN'T BE A BIG BURDEN ON THEM TO LOOK AT THIS
2	LIMITED AMOUNT OF INFORMATION AND COME TO A QUICK
3	DECISION ON WHETHER IT AFFECTS THEIR SCORES OR NOT.
4	THAT'S WHAT WAS DRIVING THE FORMULATION OF
5	THIS POLICY. BUT I THINK WE'RE AT A POINT WHERE
6	WE'RE RUNNING OUT OF TIME, PEOPLE NEED TO MOVE ON.
7	WE CAN HAVE ANOTHER MEETING TO LOOK AT THIS. UNLESS
8	SOMEONE WANTS TO MAKE A MOTION TO ADOPT THIS OR IF
9	OS WOULD LIKE TO MAKE A MOTION ON THE IDEA THAT HE
10	HAS, MAYBE WHAT WE COULD DO, IF PEOPLE COULD SEND
11	MELISSA ANY IDEAS THAT YOU HAVE AND SHE CAN SEND
12	THEM SPECIFICALLY TO ME. IF I DON'T SHARE THEM WITH
13	ANYBODY ELSE, I DON'T VIOLATE BAGLEY-KEENE AND WE
14	CAN TALK TO STAFF AND COME UP WITH PERHAPS ANOTHER
15	BITE AT THE APPLE OR IS THAT PROBLEMATIC?
16	MR. TORRES: ON THAT POINT, I JUST WANT TO
17	REITERATE. I THINK WE HEARD WHAT TOOK PLACE BEFORE
18	IN THE ABOUDI SITUATION THAT ALAN ARTICULATED. IT
19	SEEMS TO BE THE ALTERNATIVE, AND THAT IS IF THERE'S
20	AN OPPORTUNITY TO DO THAT, SEARCH OUT THE EXPERTISE,
21	GET AN OUTSIDE REVIEW, LIKE DUANE AND DR. PIZZO AND
22	OS HAVE INDICATED, AND LET'S GO WITH IT, BUT ALLOW
23	ENOUGH FLEXIBILITY TO DO THAT. SO I THINK WE STILL
24	NEED TO THINK IT THROUGH TO SEE HOW THAT WOULD BE
25	WORDED.
	/ 7

1	MR. ROTH: I WANT TO JUST FOLLOW UP ON
2	THAT AND SUGGEST THAT THIS HAS BEEN A VERY GOOD
3	DISCUSSION, BUT I DON'T THINK IT'S TIME TO TAKE
4	ACTION TODAY. BECAUSE THE PUBLIC HASN'T HAD A LOT
5	OF TIME TO LOOK AT THIS, MAYBE WE'LL GET SOME GOOD
6	INPUT FROM THE PUBLIC ON HOW WE MIGHT HANDLE THIS.
7	DR. STEWARD: I WOULD NOT MAKE A MOTION
8	FORMALLY ON MY PROPOSAL EITHER, BUT I WOULD LIKE TO
9	PROPOSE IT AS SOMETHING THAT WE ALL THINK ABOUT.
10	I'D BE HAPPY TO WRITE UP A LITTLE THING OR PERHAPS
11	IF STAFF WANTED TO DO THAT, THAT'S GREAT, WHICHEVER.
12	DR. PIZZO: THAT WOULD BE GREAT.
13	CHAIRMAN SHEEHY: WE WOULD NOT VIOLATE
14	BAGLEY-KEENE. SINCE THIS HAS BEEN DISCUSSED IN
15	PUBLIC AS OS FLESHED OUT HIS PROPOSAL, AND WE WERE
16	ABLE TO WORK WITH ATTORNEYS AND STAFF TO MAKE IT A
17	MORE FULLY REALIZABLE PROPOSAL FOR A FUTURE MEETING
18	OF THE SCIENCE SUBCOMMITTEE.
19	DR. PIZZO: OKAY. SIGNING OFF.
20	CHAIRMAN SHEEHY: I'D LIKE TO NOT FORMALLY
21	ADJOURN YET. SO IF MEMBERS NEED TO GO, WE'RE NOT
22	GOING TO CONSIDER ANYTHING ELSE TODAY, BUT I WANTED
23	TO GIVE ANY MEMBER OF THE PUBLIC OR ANYONE ELSE A
24	CHANCE TO MAKE ANY OTHER COMMENTS. DON REED.
25	MR. REED: THIS IS LIKE WINSTON CHURCHILL
	68

I	SALD. THE TOUGH DECISIONS ARE 51 PERCENT AND 49
2	PERCENT. THIS IS A VERY TOUGH ONE. EVERYONE IS
3	GOING THE EXTRA MILE TO FIND THE BEST POSSIBLE WAY.
4	I DO LIKE THE IDEA OF WHEN THINGS ARE SO CLOSE, TO
5	HAVE OUTSIDE AUTHORITY BROUGHT IN, BUT IT IS A TOUGH
6	DECI SI ON.
7	CHAIRMAN SHEEHY: CHAIRMAN KLEIN.
8	CHAIRMAN KLEIN: I'D JUST LIKE TO CLARIFY
9	FOR THE RECORD THAT, JEFF, YOU'VE SPOKEN MANY TIMES
10	ABOUT HOW EFFECTIVE THE PEER REVIEW SYSTEM IS. AND
11	CERTAINLY THE EXTRAORDINARY PETITION PROCESS HAS
12	GIVEN US THE ABILITY, WORKING WITH THE STAFF, THAT
13	HAD THE HIGH POTENTIAL WHERE THERE WAS AN ERROR LIKE
14	THE ABOUDI GRANT. SO I THINK THAT WHAT WE'RE REALLY
15	DOING IS A VERY HIGH STANDARD. WE'RE REACHING TO
16	TRY AND IMPROVE THE SYSTEM, TO FIND THAT
17	BREAKTHROUGH GRANT WE MIGHT OTHERWISE PASS OVER.
18	BUT I WOULD IDENTIFY WITH WHAT JOAN SAID. WE'RE
19	TRYING TO DO IMPROVEMENTS HERE, AND WE HAVE A BROKEN
20	CAPACITY TO GET THAT LAST GRANT, BUT THAT'S WHAT
21	WE'RE REACHING FOR IN A SYSTEM THAT OTHERWISE IS
22	WORKING PRETTY WELL.
23	CHAIRMAN SHEEHY: DO WE HAVE ANY OTHER
24	COMMENTS FROM MEMBERS OF THE BOARD OR FROM ANYONE AT
25	ANY OTHER SITE?

```
1
                 MR. TORRES: JUST TO THANK YOU FOR THE
 2
      DI SCUSSI ON.
 3
                 CHAIRMAN SHEEHY: THEN WE'RE ADJOURNED.
 4
      THANK YOU.
                      (THE MEETING WAS THEN ADJOURNED AT
 5
      12: 05 P.M.)
 6
 7
 8
 9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
                                  70
```

REPORTER'S CERTIFICATE

I, BETH C. DRAIN, A CERTIFIED SHORTHAND REPORTER IN AND FOR THE STATE OF CALIFORNIA, HEREBY CERTIFY THAT THE FOREGOING TRANSCRIPT OF THE TELEPHONIC PROCEEDINGS BEFORE THE SCIENCE SUBCOMMITTEE OF THE INDEPENDENT CITIZEN'S OVERSIGHT COMMITTEE OF THE CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE IN THE MATTER OF ITS REGULAR MEETING HELD ON TUESDAY, JULY 20, 2010, WAS HELD AS HEREIN APPEARS AND THAT THIS IS THE ORIGINAL TRANSCRIPT THEREOF AND THAT THE STATEMENTS THAT APPEAR IN THIS TRANSCRIPT WERE REPORTED STENOGRAPHICALLY BY ME AND TRANSCRIBED BY ME. I ALSO CERTIFY THAT THIS TRANSCRIPT IS A TRUE AND ACCURATE RECORD OF THE PROCEEDING.

BETH C. DRAIN, CSR 7152 BARRISTER'S REPORTING SERVICE 1072 BRISTOL STREET SUITE 100 COSTA MESA, CALIFORNIA (714) 444-4100